



Published in final edited form as:

Nat Rev Genet. 2023 March ; 24(3): 143–160. doi:10.1038/s41576-022-00534-0.

Biological roles of adenine methylation in RNA

Konstantinos Boulias^{1,2,3}, Eric Lieberman Greer^{1,2,3,✉}

¹Division of Newborn Medicine, Boston Children's Hospital, Boston, MA, USA.

²Department of Pediatrics, Harvard Medical School, Boston, MA, USA.

³Harvard Medical School Initiative for RNA Medicine, Boston, MA, USA.

Abstract

*N*⁶-Methyladenosine (*m*⁶A) is one of the most abundant modifications of the epitranscriptome and is found in cellular RNAs across all kingdoms of life. Advances in detection and mapping methods have improved our understanding of the effects of *m*⁶A on mRNA fate and ribosomal RNA function, and have uncovered novel functional roles in virtually every species of RNA. In this Review, we explore the latest studies revealing roles for *m*⁶A-modified RNAs in chromatin architecture, transcriptional regulation and genome stability. We also summarize *m*⁶A functions in biological processes such as stem-cell renewal and differentiation, brain function, immunity and cancer progression.

The RNA building block adenosine can be methylated at several distinct nitrogen atoms of the nucleobase (N1, N2 or N6) or on the 2' oxygen of the ribose (BOX 1). RNA *N*⁶-methyladenosine (*m*⁶A) was identified in mammalian mRNA in the 1970s^{1,2}, but more sensitive detection and mapping techniques (TABLE 1) have facilitated transcriptome-wide mapping of *m*⁶A methylation in mRNA and have enabled its detection in nearly all types of RNAs, including ribosomal RNAs (rRNAs), mRNAs, small nuclear RNAs (snRNAs) and several species of regulatory RNAs. The expansion of new techniques coupled with the characterization of enzymes that methylate, demethylate and bind to *m*⁶A (TABLE 2) has accelerated research in the past decade, establishing *m*⁶A as a major determinant of RNA fate. This epitranscriptomic modification affects most aspects of RNA metabolism, increasing the versatility of and information encoded in RNA, and has fundamental roles in development, organism homeostasis and disease.

Approximately 25% of mammalian mRNAs contain *m*⁶A, with an average of one to three modifications per transcript^{3,4}. However, *m*⁶A-modified transcripts seem to be highly heterogeneous from cell to cell⁵. For mRNA and other RNA Polymerase II-synthesized transcripts (including most small RNAs and microRNAs (miRNAs)), the METTL3–METTL14–WTAP methyltransferase complex is mainly responsible for the deposition of

✉ eric.greer@childrens.harvard.edu .

Author contributions

The authors contributed equally to all aspects of the article.

Competing interests

The authors declare no competing interests.

m⁶A in newly synthesized transcripts in the cell nucleus⁶ (FIG. 1a and TABLE 2). m⁶A was found to be enriched in conserved locations in the 3' untranslated regions (UTRs) and near stop codons of transcripts that regulate differentiation and development, whereas it is relatively depleted in housekeeping transcripts^{3,4}. Mapping has refined the conserved sequence of m⁶A to the motif DRACH (where D = A, G or U; R = A or G; H = A, C or U)^{3,4,7,8}. Importantly, m⁶A in mRNA is dynamic and reversible, as the methyl group can be removed by the action of the demethylases ALKBH5 (REF.⁹) and FTO¹⁰, restoring the methylated base back to the canonical adenine base (FIG. 1a). By contrast, m⁶A modification of rRNAs is thought to be constitutive. Unique highly conserved sites in the 28S and 18S rRNA of eukaryotes^{11,12} are N⁶-adenosine methylated by ZCCHC4 (REFS.^{13–16}) and METTL5 (REFS.^{16–23}), respectively.

m⁶A elicits a wide range of effects on RNA through changes in RNA stability, conformation and folding or by directly modulating the interactions of modified RNAs with binding proteins that affect RNA fate and function. Although m⁶A does not prevent Watson–Crick A:U base pairing, it does have a subtle destabilization effect on RNA²⁴, which has been proposed to be important in regulating certain types of interactions, such as between miRNAs and mRNA^{25,26}. m⁶A also destabilizes Hoogsteen base pairing²⁷ and can inhibit folding of RNA in a sequence-dependent fashion²⁸. The functional consequences of m⁶A are not restricted to the modified RNAs; once methylated RNAs are degraded, methylated adenosines can also function as signalling molecules by acting as ligands for the adenosine A3 receptor²⁹. However, the majority of the functional consequences of m⁶A methylation in RNA fate and function are thought to be mediated by m⁶A-binding proteins (TABLE 2) (reviewed elsewhere^{30,31}). In humans, the best characterized m⁶A-binding proteins belong to the YTH family^{3,4,30,32}, but other binding proteins include insulin-like growth factor 2 binding proteins (IGF2BPs)³³ and fragile X mental retardation protein (FMRP)³⁴. By contrast, the presence of m⁶A has been shown to prevent binding of certain proteins, including the G3BP stress granule proteins³⁴.

In this Review, we focus on the functions of RNA m⁶A methylation at the molecular, genomic and organismal level. We describe the functional consequences of m⁶A deposition on RNA substrates, including mRNA, rRNAs and regulatory RNAs. We review recent advances that clarify the mechanisms by which RNA methylation has an impact on chromatin architecture, epigenetic regulation of gene expression and genome stability. Finally, we summarize the key roles of m⁶A in fundamental biological processes during early development and in adult tissue homeostasis, including stem-cell differentiation, neurogenesis and brain function, and innate immune response, as well as m⁶A dysregulation in diseases, such as cancer.

Molecular consequences of m⁶A on RNA

At the molecular level, m⁶A participates in nearly every aspect of RNA metabolism, including mRNA expression^{3,4}, splicing^{4,26,35}, nuclear export^{9,36}, translation efficiency^{37–40}, RNA stability^{41,42} and miRNA processing^{43,44}. Its effect on these processes seems to be largely regulated by binding proteins. However, the specific determinants that

dictate whether an m⁶A-modified RNA is regulated at the level of splicing, export, stability or translation, or at multiple levels, are still unclear.

m⁶A mediates pre-mRNA splicing and nuclear export.

m⁶A affects the alternative splicing of mRNAs either through its direct interaction with nuclear reader YTHDC1 or through an ‘m⁶A switch’ mechanism involving indirect binding of heterogeneous nuclear ribonucleoproteins (HNRNPs), which are abundant nuclear proteins known to regulate pre-mRNA processing (FIG. 1b). Work in *Drosophila melanogaster*^{45,46} and human cell lines⁴⁷ demonstrated that YTHDC1 binds directly to m⁶A-modified mRNAs and modulates alternative splicing by recruiting the splicing factor SRSF3, which promotes exon inclusion, and by inhibiting binding of splicing factor SRSF10 to drive exon skipping (FIG. 1b). In an example of the m⁶A-switch mechanism, m⁶A affects the conformation of local RNA structure by exposing the HNRNPC binding motif, which in turn promotes exon retention²⁶ (FIG. 1b). Future work will need to decipher how specificity of splicing is determined for interactions with YTHDC1 or HNRNPs.

m⁶A-Binding proteins also facilitate interactions with nuclear export components to regulate the subcellular localization of modified mRNAs. YTHDC1 binds to the export proteins SRSF3 and NXF1, and FMRP physically associates with the export protein CRM1 to accelerate the export of N⁶-adenosine methylated transcripts from the nucleus^{48–50} (FIG. 1c). Thus, m⁶A seems to facilitate shuttling of mRNAs to the cytoplasm for translation by multiple mechanisms. It remains to be determined how nuclear export specificity is determined and whether these two pathways function independently or coordinate to facilitate nuclear export and subsequent processing in the cytoplasm.

m⁶A regulates mRNA degradation and stability.

Initial work in mouse embryonic stem (mES) cells demonstrated that m⁶A-modified mRNAs are less stable than unmodified transcripts, resulting in their reduced abundance and translation potential⁵¹. Subsequent studies showed that m⁶A-marked transcripts are actively targeted for degradation through direct binding to YTHDF2 (REFS.^{52,53}), which recruits the CCR4–NOT deadenylase complex, a complex responsible for mRNA decay⁵² (FIG. 1d). Alternatively, YTHDF2 can physically interact with HRSP12 to recruit RNaseP/MRP endoribonucleases to cleave m⁶A transcripts⁵³. However, the effects of m⁶A on stability seem to be complex, as binding of IGF2BPs to methylated mRNAs stabilizes them by protecting them from degradation³³ (FIG. 1d). Furthermore, work in the parasite *Trypanosoma brucei* found that when methylation of the polyA tail of transcripts occurs in conjunction with variant surface glycoproteins, there is an increase in mRNA stability⁴². Taken together, these data suggest that additional factors determine whether m⁶A-containing transcripts are degraded or stabilized; additional work is needed to determine what these factors might be.

m⁶A promotes or inhibits mRNA translation in a context-dependent manner.

m⁶A promotes translation rates by multiple mechanisms depending on the location of m⁶A within the mRNA transcript. If m⁶A is located at the 5′ UTR, it can promote cap-independent translation in response to stress through binding of eukaryotic translation

initiation factor 3 (eIF3), which directs the recruitment of the 43S translation complex to initiate translation³⁷ (FIG. 1e). When m⁶A is located in the 3' UTR, it can promote cap-dependent translation through direct interactions with YTHDF1 or YTHDF3, resulting in enhanced translation^{38,54} (FIG. 1e). YTHDF1 is postulated to affect translation initiation at the 5' end of the transcript through a physical interaction with eIF3 that results in the looping of YTHDF1 to the transcriptional start site³⁸ (FIG. 1e). However, m⁶A on mRNAs has also been shown to inhibit translation by affecting the interaction of transcripts with tRNAs, thereby slowing translation elongation⁵⁵ (FIG. 1e).

m⁶A on rRNA refines ribosome binding.

rRNAs are modified at more than 200 nucleotides⁵⁶ (Box 1). However, they are N⁶-adenosine methylated at only two conserved positions, corresponding to adenosine 1832 of human 18S rRNA and adenosine 4220 of human 28S rRNA. Recent discovery of the 28S rRNA methyltransferase *ZCCHC4* in mammals^{13,14} and the 18S rRNA methyltransferase *METTL5* in various Metazoans^{16–21} has begun to shed light on the functional role of these methylations in regulating translation (FIG. 2a). Genetic knockout of *ZCCHC4* in mammalian cell lines resulted in a reduction of global translation and inhibition of cell proliferation of hepatocellular carcinoma cell lines¹³. Loss of 18S m⁶A methylation by genetic knockout or knockdown of *Mettl5* resulted in a wide range of phenotypes, including loss of pluripotency and decreased differentiation potential in mES cells^{18,21}, increased stress resistance in *Caenorhabditis elegans*¹⁷ and behavioural defects in *D. melanogaster*²⁰. Together, these findings raise the possibility that m⁶A in rRNAs can expand ribosome heterogeneity, which could induce the translation of specific sets of transcripts under different contexts or in response to diverse stimuli to regulate specific cellular processes.

m⁶A mediates microRNA processing.

In mRNAs, m⁶A and miRNA binding sites are both enriched in the 3' UTR and near stop codons, leading to the proposal that crosstalk might occur between them in miRNA-dependent control of gene expression³. Indeed, m⁶A is enriched at miRNA binding sites in mouse embryonic fibroblasts and human cancer cell lines^{57–59}, and depletion of Dicer, a regulator of biogenesis of mature miRNA, results in reduced m⁶A deposition in these cells. Whether m⁶A on mRNAs can have an impact on the targeting of miRNAs is still unclear. However, m⁶A directly affects miRNA processing and biogenesis of mature miRNAs. The miRNA microprocessor complex subunit DGCR8 is recruited to m⁶A-modified primary (pri)-miRNAs, usually via the HNRNPA2B1 m⁶A-binding protein, and pri-miRNAs are then processed to mature miRNAs; depletion of m⁶A from pri-miRNAs disrupts this process and leads to lower levels of mature miRNAs^{43,44} (FIG. 2b). These findings begin to illustrate how m⁶A could affect the biogenesis of specific miRNAs, and thereby add another level of regulation to miRNA-mediated gene silencing.

m⁶A promotes circular RNA biogenesis and function.

Circular RNAs (circRNAs) are frequently produced by back-splicing of exons, whereby a 5' splice donor site is fused to an upstream 3' splice acceptor site⁶⁰. The functions of circRNAs are just beginning to be characterized, but some circRNAs suppress specific miRNAs by functioning as miRNA 'sponges'^{61,62}. Growing in vitro and in vivo evidence suggests

that N^6 -adenosine methylation of circRNAs regulates their biogenesis and translation potential^{63,64}. A single m^6A is sufficient to initiate cap-independent translation of an artificial circRNA reporter construct⁶³ and can increase circRNA biogenesis and stimulate cap-independent translation from an open reading frame in circ-ZNF609 via binding of YTHDF3 and eIF4G2 (REF.⁶⁴) (FIG. 2c). Although the functions of polypeptides derived from circRNA-encoded open reading frames are still unknown, the fact that circRNA biogenesis and translation are modulated by m^6A implies that these by-products of alternative splicing of exons have important regulatory functions.

m^6A modulates spliceosome assembly and function.

The deposition of m^6A in snRNAs, such as the spliceosome component U6 snRNA, is mediated by the METTL16 methyltransferase^{65,66}. METTL16 specifically modifies adenosine 43 (A43) in U6 snRNA^{65,66}, but it is unclear whether this modification is constitutive or reversible (FIG. 2d). Interestingly, A43 of U6 snRNAs interacts with the 5' splice site of pre-mRNAs and it has been proposed that A43 methylation might fine-tune snRNA-pre-mRNA interactions, thereby regulating spliceosome assembly at, or recognition of, the 5' splice site⁶⁶. These findings suggest that m^6A can have a dual role in pre-mRNA splicing: in addition to regulating alternative splicing in subsets of m^6A -modified transcripts as discussed above, it can also directly modulate spliceosome function.

m^6A , chromatin and genome integrity

In the past decade, it has become increasingly clear that N^6 -adenosine methylation is not only instrumental in regulating RNA fate and metabolism but also has broader roles in epigenetic regulation of gene expression, in shaping genomic architecture and maintaining genomic stability. These effects of m^6A on genome stability and function were found to be mediated by various types of RNAs, including nascent pre-mRNA transcripts, long non-coding RNAs (lncRNAs), chromosome-associated regulatory RNAs (carRNAs), endogenous retrovirus RNAs (ERVs) and R-loops.

m^6A in pre-mRNA mediates crosstalk with chromatin modifications.

Several lines of evidence indicate extensive crosstalk between m^6A in pre-mRNAs and chromatin modifications, providing an additional layer of regulation in the control of gene expression and genome stability. Mapping experiments show that m^6A on mRNAs overlaps significantly with high levels of histone H3 trimethylated at lysine 36 (H3K36me3) at the corresponding genomic location, and deletion of the H3K36 trimethyltransferase SETD2 results in global reduction of m^6A levels and reduced levels of METTL3 complexes binding to target mRNAs⁶⁷. Interestingly, METTL14 binds to H3K36me3-modified histones and recruits METTL3 to sites that are actively transcribed by RNA polymerase II so that m^6A is deposited co-transcriptionally⁶⁷. Reciprocally, co-transcriptional N^6 -adenosine methylation of nascent mRNA transcripts facilitates the removal of H3 dimethylated at lysine 9 (H3K9me2), a traditionally repressive histone modification⁶⁸, via recruitment of the H3K9me2 demethylase KDM3B, which physically interacts directly with the m^6A -binding protein YTHDC1 (REF.⁶⁸) (FIG. 3a). The N^6 -adenosine methyltransferase complex also directly regulates transcription by inducing the release of RNA polymerase II from a paused

state⁶⁹, and the presence of m⁶A inhibits binding of the transcriptional termination integrator complex⁷⁰. This coordinated communication between m⁶A and the chromatin modifying machinery further highlights how epitranscriptomic and epigenetic modifications form a complex regulatory network with multiple modules and switches that increase the flexibility of gene expression control.

m⁶A can also indirectly affect chromatin modifications, and presumably other methylated substrates, by regulating levels of the predominant methyl donor, *S*-adenosyl methionine (SAM). METTL16, whose homologue is essential for mouse embryonic development⁷¹, mediates m⁶A methylation of a hairpin in the 3' UTR of *MAT2A* pre-mRNA (encoding the SAM synthetase protein). When unmodified, this hairpin inhibits splicing of *MAT2A* transcripts, causing intron retention and RNA decay, thereby limiting SAM levels⁶⁵. However, when the levels of SAM are too low, METTL16 is recruited to and methylates the 3' UTR hairpin, which facilitates efficient splicing of *MAT2A* pre-mRNA and stimulates SAM synthesis⁶⁵. By contrast, in *C. elegans*, METT-10 (the worm orthologue of METTL16) inhibits endogenous SAM bio-synthesis via a negative feedback loop in response to changes in diet that increase intracellular SAM levels⁷²; METT-10-mediated N⁶-adenosine methylation of *sams3* transcripts (which encode SAM synthetase) at their 3' splice sites inhibits their splicing, leading to lower levels of SAM⁷². Maintaining appropriate SAM levels via METT-10/METTL16 seems to be a conserved process, albeit through inhibition or promotion of SAM synthesis depending on the organism. This work exemplifies some of the crosstalk that mRNA methylation can have with other epigenetic cues including histone methylation.

m⁶A in lncRNAs facilitates oncogenesis and X chromosome gene silencing.

Initial mapping in mouse tissue and human cell line studies revealed that m⁶A is prevalent in lncRNAs^{3,4}, and subsequent studies have revealed important biological consequences of m⁶A for the functions of the lncRNAs *Xist* (which has a pivotal role in X chromosome inactivation)⁷³ and *Malat1* (an abundant nuclear lncRNA that is often upregulated in metastatic cancers).

Directed by the lncRNA *Rmb15*, METTL3 methylates 78 sites in lncRNA *Xist*⁷⁴, which causes YTHDC1 to bind to *Xist*, an interaction that is required for X chromosome inactivation (FIG. 3b). In an elegant experiment, the artificial tethering of YTHDC1 to *Xist* bypasses the requirement for m⁶A for transcriptional repression of the X chromosome, indicating that the primary function of m⁶A is to recruit YTHDC1 to *Xist*⁷⁴ (FIG. 3b). However, the extent of the involvement of m⁶A in X chromosome inactivation and how YTHDC1 influences *Xist*-mediated gene silencing remain unclear, although it has been proposed that YTHDC1 facilitates the interaction of *Xist* with gene silencing proteins^{74,75}.

Malat1 is known to localize to nuclear speckles, associate with splicing factors and affect the expression of oncogenes through interactions with transcription factors and chromatin modifying enzymes⁷⁶. It has recently been shown that m⁶A modifications in *Malat1* create a scaffold for the recruitment of YTHDC1 in nuclear speckles. Both the m⁶A modifications in *Malat1* and the YTHDC1 localization to nuclear speckles seem to be necessary for the oncogenic effects of *Malat1* (REF.⁷⁷). N⁶-Adenosine methylation of *Malat1* has also

been proposed to destabilize an RNA hairpin, thereby exposing an RNA-binding motif and promoting interaction with HNRNPC²⁶ (FIG. 3c); although the functional consequences of this interaction remain unclear, binding presumably facilitates the localization of HNRNPC to nuclear speckles.

As lncRNAs have been shown to play roles in various processes, ranging from regulating the immune system, to development, to regulating genome stability and ageing⁷⁸, the prevalence of m⁶A on lncRNAs could, in turn, affect each of these processes by altering binding of specific lncRNAs to proteins, RNAs or DNA or through modulation of local RNA structure.

m⁶A in carRNAs and ERVs suppresses expression of repetitive elements.

m⁶A on regulatory RNA species could facilitate communication between RNAs and chromatin to help reinforce the functional consequences of m⁶A. Deletion of the m⁶A methyltransferase *Mettl3* or binding protein *Ythdc1* in mES cells resulted in reduced m⁶A levels on several classes of carRNAs, such as promoter-associated RNAs, enhancer RNAs and repeat RNAs, and in broad increases in chromatin accessibility and transcriptional activation^{79,80}. m⁶A was shown to facilitate the degradation of certain carRNAs, such as long interspersed element 1 (LINE-1; also known as L1) repeat RNAs, by recruitment of the nuclear exosome targeting complex (NEXT)⁷⁹ (FIG. 3d). As L1 repeat RNAs promote chromatin accessibility during transcriptional activation, the m⁶A-mediated decay of specific carRNAs might regulate the chromatin state during mES cell homeostasis.

Suppression of expression from large swaths of repetitive DNA is essential for cell viability and the regulated expression of appropriate transcripts. Repetitive elements and retrotransposons can cause genomic instability by inducing recombination-mediated chromosomal rearrangements, such as deletions, insertions and trans-locations, that affect the expression of nearby genes or by causing mutations through transposition events in the genome⁸¹. In a genome-wide CRISPR–Cas9 screen in mES cells, several components of the *Mettl3* complex were shown to be required for the repression of the intracisternal A-particle (IAP)-type family of ERVs⁸². The suppression of these IAPs is mediated by N⁶-adenosine methylation of the 5' UTRs of *IAP* mRNAs, which promotes their decay through an YTHDF2-dependent mechanism⁸² (FIG. 3e). METTL3 also facilitates heterochromatin formation and subsequent transcriptional repression by binding and recruiting the H3K9me3 methyltransferase SETDB1 to IAP-encoding genomic regions⁸³ (FIG. 3e).

Taken together, these studies reveal that N⁶-adenosine methylation can facilitate chromatin reorganization to regulate the appropriate suppression of retrotransposons to safeguard genome stability.

m⁶A promotes genome stability at R-loops.

R-loops are frequently formed during transcription and have roles in transcription initiation and elongation, replication and DNA repair⁸⁴. Interestingly, the RNA strand of R-loops is often N⁶-adenosine methylated by METTL3 in human pluripotent stem cells⁸⁵. Depletion of the m⁶A-binding protein YTHDF2 results in accumulation of m⁶A-methylated R-loops, leading to cell growth retardation and increased accumulation of histone γ H2AX, a marker of DNA double-strand breaks⁸⁵. These results suggest that m⁶A in R-loops mediates R-loop

removal, thereby safeguarding genome stability, but the underlying mechanism of YTHDF2-mediated R-loop degradation remains unclear (FIG. 3f). There may be a dual or context-dependent role for m⁶A in R-loop formation and maintenance, as an earlier study performed in HeLa cells suggested that m⁶A promotes R-loop formation to facilitate transcription termination⁸⁶. Interestingly, DNA damage signals induce the ataxia-telangiectasia mutated (ATM) protein to phosphorylate METTL3, which is then recruited to sites of double-strand breaks in R-loops where it methylates the RNA strand at N⁶-adenosines⁸⁷. Subsequent recruitment of YTHDC1 causes an increased accumulation of RNA:DNA hybrids, which results in the recruitment of RAD51 and BRCA1 to drive homologous recombination-mediated repair⁸⁷. Therefore, the N⁶-adenosine methylation of RNA in R-loops seems to induce a multipronged, context-specific response that can regulate numerous biological consequences of R-loop formation.

m⁶A in development and differentiation

Given the emerging roles of m⁶A as a versatile modification that regulates RNA metabolism, protein synthesis, gene expression and genome stability, it is unsurprising that m⁶A regulates diverse biological processes during development, differentiation and adult tissue homeostasis. The importance of m⁶A in early developmental decisions is underscored by the fact that METTL3 and METTL14 are essential for mouse and plant embryonic development^{88–90}. In this section, we explore the roles of m⁶A in stem-cell renewal and differentiation, and in developmental transitions.

m⁶A facilitates ES cell self-renewal and differentiation.

The role of m⁶A in regulating the stem-cell state is highlighted by the observation that genetic knockdown of components of the METTL3–METTL14 complex in mES cells causes a loss of self-renewal capacity owing to the increased stability of N⁶-adenosine methylated pluripotency factors such as Nanog, SOX2 and KLF4 (REFS.^{51,88,91}). Furthermore, genetic knockout of *METTL3* or *METTL14* in mES cells and human ES cells disrupts their exit from the self-renewal pathway and progression towards differentiation⁹¹, resulting in a failure to undergo lineage priming and transition to the post-implantation primed stage leading to embryonic lethality^{88,89}. METTL3 complex localization is regulated by two opposing zinc-finger proteins. ZFP217, a transcriptional activator of core pluripotency genes, binds to and sequesters METTL3, thereby limiting m⁶A deposition on transcripts required for pluripotency, resulting in impaired stem-cell renewal⁹². Conversely, ZC3H13 anchors the m⁶A methyltransferase complex in the nucleus of mES cells, facilitating m⁶A deposition and promoting stem-cell renewal⁹³ (FIG. 4a). Importantly, the deposition of m⁶A on transcripts encoding pluripotency factors is responsive to extracellular signalling cues. Activation of TGFβ–activin signalling in human pluripotent stem cells leads to the physical association of transcription factors SMAD2/3 with the METTL3–METTL14–WTAP methyltransferase complex, promoting m⁶A deposition on a subset of mRNAs encoding pluripotency factors, including Nanog⁹⁴. Conversely, inhibition of TGFβ–activin signalling destabilizes these mRNAs and causes their rapid degradation, allowing a timely exit from pluripotency and the induction of neuroectoderm differentiation⁹⁴. Precisely how the changes in N⁶-adenosine methylation are interpreted is still unclear. The

YTHDF2 binding protein is a good candidate for interpreting changes in m⁶A in stem cells as it has recently been implicated in destabilizing neural-specific RNA transcripts during induced pluripotent stem cell differentiation⁹⁵. However, owing to the functional redundancy of YTHDF proteins, it is plausible that other members of the family might also contribute to the degradation of core pluripotency factor transcripts⁹⁶. Taken together, these findings underscore the importance of m⁶A in regulating ES cell renewal, differentiation and pluripotency through marking key transcripts that maintain cell state or facilitate differentiation.

m⁶A facilitates developmental transitions.

During oocyte maturation and early embryogenesis, development is driven by the inherited pool of maternal mRNA transcripts. The activation of zygotic transcription occurs during the tightly regulated maternal-to-zygotic transition (MZT)⁹⁷. In zebrafish, N⁶-adenosine methylation of mRNAs plays a critical role in the clearance of maternal mRNAs, as approximately one third of maternal transcripts are m⁶A-modified and elimination of YTHDF2 by genetic knockout limits the decay of the maternal mRNAs and delays development⁹⁸. Interestingly, YTHDF2 may not function on its own to recognize m⁶A-modified maternal transcripts, as all three YTHDF binding proteins act redundantly to control MZT and oogenesis⁹⁹ (FIG. 4b). Similarly, m⁶A is important for mouse oocyte maturation, which is also characterized by a wave of degradation of maternal mRNAs when oocytes proceed through meiosis (M-decay) and another wave in the early zygote during MZT (Z-decay). The effects of METTL3-dependent m⁶A deposition during mouse oocyte differentiation are mediated by the coordinated activity of YTHDF2, YTHDC1 and YTHDC2 (REFS.^{100–104}). Oocyte-specific inactivation of YTHDF2 causes infertility owing to impaired degradation of a subset of maternal transcripts at or prior to the two-cell stage¹⁰³. Moreover, knockdown of *Mettl3* in developing oocytes impairs maturation and MZT due to decreased mRNA translation and inefficient maternal mRNA clearance¹⁰⁵. m⁶A coordinates with other regulatory pathways to rapidly clear maternal mRNAs during MZT. In zebrafish, mir-430 is induced during MZT and facilitates the deadenylation and clearance of hundreds of maternal transcripts through binding to their 3' UTRs¹⁰⁶. The co-occurrence of m⁶A modifications and the miR-430 seed in the 3' UTR seems to accelerate the destabilization of maternal mRNAs⁹⁹ (FIG. 4b). Interestingly, other RNA modifications have also been implicated in maternal mRNA clearance during MZT in zebrafish. In contrast to m⁶A, binding of YBX1 to a pool of C5-cytosine methylation (m⁵C)-modified maternal mRNA was shown to increase their stability⁸⁶ (FIG. 4b). Moreover, addition of a uracil tail to maternal mRNAs by the terminal uridylyltransferases TUT4 and TUT7 facilitates their clearance during MZT¹⁰⁷. It will be important in future studies to decipher how m⁶A on maternal mRNAs communicates with miRNA-mediated regulation and to examine whether an epitranscriptomic code exists — a mechanistic crosstalk between m⁶A and the other RNA modifications — which facilitates the read-out of multiple mRNA modifications to elicit a stronger biological consequence.

N⁶-Adenosine methylation also seems to be critical for the endothelial-to-haematopoietic transition during zebrafish embryogenesis, a process governed by numerous interconnected signalling pathways, including NOTCH1 signalling, which drives haematopoietic stem and

progenitor cell specification¹⁰⁸. Genetic knockout of *mettl3* in zebrafish embryos blocks the production of haematopoietic stem/progenitor cells during endothelial to haematopoietic transition^{109,110}, and these effects were shown to be mediated by YTHDF2-directed degradation of *Notch1a* mRNA, resulting in reduced NOTCH1 signalling. This m⁶A-mediated regulation of endothelial-to-haematopoietic transition through NOTCH signalling is conserved in mice¹⁰⁹.

m⁶A regulates adult stem-cell differentiation.

N⁶-Adenosine methylation of mRNA is also important for the homeostasis and differentiation of adult stem-cell lineages, including haematopoietic stem cells (HSCs) and neuronal stem cells (NSCs), which is underscored by the emerging roles of m⁶A in cancer stem-cell biology especially in acute myeloid leukaemia (AML) and glioblastoma (see below). Deletion of *Mettl3* in adult mouse HSCs resulted in their impaired differentiation in vivo¹¹¹. The role of m⁶A in regulating HSCs seems to be mediated by the N⁶-adenosine methylation of *Myc* mRNAs, which enhances their translation, with the resulting increase in MYC protein driving HSC differentiation¹¹¹ (FIG. 4c). Interestingly, the results observed for a *Mettl3*-knockout mouse contradict earlier studies in human HSC cells, which reported that knockdown of *METTL3* and *METTL14* impairs human progenitor haematopoietic stem and progenitor cell self-renewal and leads to myeloid differentiation by limiting expression of the MYB and MYC transcription factor^{112,113}. These discrepancies might arise from differential effects of m⁶A methylation in progenitor cells versus adult HSC cells or in differences between knocking out and knocking down the mRNA m⁶A regulatory machinery. It will be important for future studies to resolve the role of m⁶A in adult HSC differentiation and to identify which binding proteins mediate the effects of m⁶A on MYC and other developmental regulators.

m⁶A also affects NSC renewal and differentiation in the cortex of the mouse brain. m⁶A depletion by *Mettl14* knockout or *Mettl3* knockdown prolongs the cell cycle and causes delayed differentiation of NSCs owing to increased stability of transcripts encoding neural developmental regulators that are normally kept at low levels¹¹⁴. Mouse NSCs lacking *Mettl14* show decreased proliferation and premature differentiation, suggesting a defect in their self-renewal potential¹¹⁵. Interestingly, this study demonstrated that m⁶A destabilizes the mRNAs of histone modifying enzymes, suggesting a model by which m⁶A influences NSC self-renewal and differentiation through regulation of chromatin structure¹¹⁵. The importance of m⁶A in neural lineage differentiation is further highlighted by the revelation that *Ythdf2*-knockout mice exhibit delayed cortical neurogenesis owing to impaired degradation of m⁶A-modified mRNAs associated with neuronal development and differentiation¹¹⁶. Moreover, knockout of the gene encoding the FTO demethylase causes defects in neurogenesis, which lead to impaired learning and memory owing to dysregulated gene expression in the hippocampus¹¹⁷. Taken together, these data suggest that m⁶A can regulate NSC renewal and differentiation by multiple mechanisms that involve the destabilization of neural development regulators and alterations in chromatin structure.

Organism-level effects of m⁶A

m⁶A is dynamically regulated in response to numerous physiological stimuli, and has been implicated in the control of numerous homeostatic mechanisms in the cell, including the UV-induced and acute restraint stress responses, circadian rhythm regulation, neurobehaviour and the innate immune system responses. Given the wide-ranging role of m⁶A in maintaining homeostasis, when m⁶A regulation goes awry, disease such as cancer develops^{118,119}. In the following section, we focus on three emerging roles of m⁶A: neuronal synaptic function and neurobehaviour; T cell homeostasis and immune responses; and cancer stem-cell establishment.

m⁶A in neural synaptic function and behaviour.

In addition to the roles of m⁶A in regulation of neurogenesis, and consistent with the elevated levels of m⁶A in mRNAs in adult brains³, several lines of evidence suggest a role for m⁶A in synapse activity and plasticity during learning and memory. Learning and the formation and maintenance of memory depend on activity-dependent changes in the strength of synapses in the hippocampus, which is achieved through changes in local protein synthesis¹²⁰. Several regulatory mechanisms involving polyA tail length and the activity of miRNAs and RNA-binding proteins have been implicated, but recent evidence suggests that m⁶A on mRNA can impact activity-induced local translation at the synapse. Low-input sequencing-based analysis of m⁶A in synaptosomal RNA in the forebrain revealed that ~3,000 synaptic N⁶-adenosine methylated transcripts are enriched for functions in synapse synthesis and modulation of synaptic transmission¹²¹. Interestingly, the N⁶-adenosine methyltransferase and demethylase and m⁶A-binding proteins are located in dendrites and adjacent to synapses, raising the possibility that subcellular modification or recruitment of modified mRNAs could have a role in synaptic activity¹²¹ (FIG. 5a). Excitingly, knockdown of the genes encoding the m⁶A-binding proteins YTHDF1 or YTHDF3 in cultured hippocampal pyramidal neurons reduces translation of the dendritically localized *Arc* mRNAs, which encode a synaptic protein that promotes internalization of specific glutamate receptors important for fast excitatory neurotransmission; the knockout cells also showed synaptic dysfunction and impaired synaptic transmission¹²¹ (FIG. 5a). Conversely, axon-specific knockdown or chemical inhibition of FTO promotes local translation of mRNAs in axons of cultured neurons¹²².

Numerous recent studies report that dynamic regulation of m⁶A in response to experience or acute stress is required for regulation of complex behaviours such as fear conditioning^{123–125}. Fear conditioning results in a rapid decrease in expression of FTO demethylase in the mouse medial prefrontal cortex and near synapses in the hippocampal CA1 neurons, with a concomitant increase in m⁶A levels^{123,124}. Targeted depletion of FTO or METTL3 in the medial prefrontal cortex or hippocampus results in enhanced fear memory consolidation following behavioural training^{123–125}. Given the opposing activities of FTO and METTL3 with respect to m⁶A deposition, and the fact that FTO can also demethylate the cap-adjacent dimethyladenosine (m⁶Am) modification¹²⁶ (Box 1), it is possible that some of the FTO-dependent behavioural effects are mediated by m⁶Am. These results raise the possibility that, following experience, changes in m⁶A deposition near

synapses could result in enhanced local translation of synaptic transcripts that facilitate memory consolidation. In support of this hypothesis, conditional inactivation of *Mettl3* specifically in the hippocampus results in long-term memory defects owing to impaired translation of early response synaptic transcripts, whereas *Mettl3* overexpression enhances learning efficacy and long-term memory formation¹²⁷. Similarly, *Ythdf1*-knockout mice display defects in translation of m⁶A-methylated transcripts following neuronal stimulation which correlate with defects in hippocampal synaptic transmission and learning and memory¹²⁸. Taken together, these studies support a model whereby m⁶A facilitates local translation of synaptic transcripts to facilitate synaptic signalling and confer memory consolidation.

m⁶A in T cell homeostasis and innate immune response.

m⁶A on mRNA has been shown to have critical roles in the immune response, including modifying T cell proliferation and differentiation, regulating the turnover of essential host transcripts and methylating viral transcripts to facilitate evasion of the host immune system. Deletion of *Mettl3* or *Mettl14* in naive T cells blocks proliferation and differentiation to effector T cells¹²⁹. Loss of N⁶-adenosine methylation on transcripts encoding inhibitors of STAT5 increased their stability, causing inhibition of STAT5 and subsequent disruption of T cell homeostasis¹²⁹. Additionally, the mRNA encoding interferon- β (IFN β) (the main cytokine in the type I interferon response) is N⁶-adenosine methylated, enabling its fast turnover following activation of the immune response¹³⁰ (FIG. 5b). CRISPR-induced depletion of m⁶A (through deletion of *METTL3*) or reducing the ability of cell to detect and respond to m⁶A (through depletion of the m⁶A-binding protein *YTHDF2*) in both human and mouse cells results in interferon stabilization and activation of interferon-stimulated genes, thereby facilitating protection against viral proliferation¹³⁰.

Host immune systems have used m⁶A methylation to effectively fight viral infections. In response to infection with vesicular stomatitis virus (VSV), macrophages inhibit the enzymatic activity of ALKBH5 (an m⁶A demethylase) resulting in a concomitant increase in m⁶A levels on RNA¹³¹. Mechanistically, it was shown that increased m⁶A methylation on mRNA encoding 2-oxyglutarate dehydrogenase (OGDH) reduces its stability and OGDH protein expression, which leads to reduced levels of a metabolite (itaconate) required for viral replication¹³¹ (FIG. 5b). Therefore, m⁶A-mediated degradation of OGDH transcripts in macrophages prevents viral proliferation.

Unsurprisingly, viruses have also evolved mechanisms that take advantage of m⁶A mRNA methylation to evade the host immune system. The RIG-I and MDA5 RNA receptor sensing pathways, which are normally activated upon recognition of unmethylated viral RNA, trigger the expression of type I interferons¹³². However, human metapneumovirus (HMPV), a negative-sense single-strand RNA virus, possesses m⁶A on its viral RNAs, which promotes viral replication and facilitates evasion of the innate immune response in human cells. Interestingly, depletion of m⁶A from HMPV RNA enhances binding and activation of RIG-I and the interferon response pathway¹³³. In a separate example, VSV infection causes the translocation of METTL3 to the cytoplasm and m⁶A deposition on viral RNAs, which facilitates its evasion of the RIG-I and MDA5 sensing pathways. Depletion

of m⁶A from VSV viral RNAs enhances the formation of double-stranded RNA domains that are recognized by RIG-I and MDA5 to trigger the activation of the interferon response pathway¹³⁴. Double-strand DNA viruses and certain single-strand RNA viruses can also generate viral circRNAs, which similarly to viral RNAs trigger the RIG-I innate immune response pathway when unmethylated¹³⁵. Taken together, these findings suggest that diverse viruses use m⁶A to abrogate the host cell immune response.

m⁶A in cancer stem cells in acute myeloid lymphoma and glioblastoma.

m⁶A is central to the regulation of RNA metabolism and fate in numerous developmental and homeostatic cellular processes, and thus disruption of the genetic networks that establish, modulate and bind to m⁶A ultimately leads to pathologies such as cancer, psychiatric disorders and metabolic disorders^{118,119}. m⁶A dysregulation has been implicated in various human cancers including breast cancer, hepatic cancers, brain cancer, cervical cancer, lung cancer and leukaemias (for a review of m⁶A role in cancer, see REF.¹¹⁸). Here, we briefly highlight some of the roles of m⁶A in cancer stem cells, using AML and glioblastoma as examples.

Given the importance of N⁶-adenosine methylation for the homeostasis of the HSC and NSC lineages, it is unsurprising that m⁶A plays a critical role in AML, an aggressive clonal disorder of HSCs, and in the tumorigenesis of glioblastoma stem-like cells (GSCs). METTL3 and METTL14 promote the m⁶A-dependent translation of MYC and MYB transcription factors, which are both activated and causal for the development of AML, indicating that m⁶A can enable the maintenance and self-renewal of leukaemia stem/initiation cells and the survival of AML cell lines^{112,113}. However, (R)-2-hydroxyglutarate (R-2HG), which inhibits FTO activity and increases m⁶A levels, inhibits the proliferation of leukaemia cells by inducing the degradation of m⁶A-modified transcripts, including those encoding MYC¹³⁶. YTHDF2 has been implicated in mediating some of the effects of m⁶A in the progression of AML; inactivation of YTHDF2 increases the half-life of m⁶A-modified transcripts and, specifically, compromises cancer stem-cell initiation and propagation¹³⁷. YTHDC1 has also been shown in ex vitro studies to be required for AML tumorigenesis by sequestering N⁶-adenosine methylated transcripts to specific regions of the cell to prevent their degradation¹³⁸.

Similarly, knockdown or overexpression of the genes encoding METTL3/METTL14 or FTO, respectively, alters the self-renewal and tumorigenesis of GSCs¹³⁹. In addition, the ALKBH5 demethylase is required for the proliferation and tumorigenesis of GSCs, as inactivation of ALKBH5 inhibits the proliferation of GSCs. ALKBH5 demethylates transcripts encoding the FOXM1 transcription factor, leading to increased FOXM1 expression and stimulation of cell proliferation¹⁴⁰. Taken together, these findings underscore the critical roles of m⁶A in tumorigenesis of cancer stem cells and provide a rationale for targeting components of the m⁶A machinery for the development of cancer therapeutics.

Conclusions and future perspectives

In this Review, we have delineated the chemical consequences of adenine methylations on RNA, described the functional effects of methylation of various different substrates and

provided illustrative examples of how these methylation events affect various biological processes, including stem-cell pluripotency, memory formation, immune responses and tumorigenesis. It has become clear that the addition of this small chemical moiety to RNA (which can physically alter the RNA or signal to binding proteins to treat the RNA molecule differently) plays an outsized role in regulating virtually every aspect of biology.

With so many diverse functions assigned to m⁶A, the next step for the field will be to distinguish direct consequences of this modification from secondary or tertiary consequences that have been inappropriately ascribed to m⁶A. Independent validation of m⁶A functions using orthogonal approaches will be necessary, and we believe that analysing the functional consequences of directed RNA methylation or demethylation of specific residues⁷⁹ will play an important part in confirming the biological importance of m⁶A. Moreover, complementing directed editing with directed chemical labelling of specific m⁶A modifications¹⁴¹, for accurate visualization and tracking, will further bolster confidence in specific biological consequences of m⁶A.

Moving forwards, it will also be important to determine how different epitranscriptomic modifications communicate with each other and with chromatin modifications, and whether an epitranscriptomic code exists that can help integrate m⁶A modifications with other epitranscriptomic or epigenetic signalling pathways. In addition, questions remain about how this abundant modification, which has been implicated in regulating so many diverse processes, can achieve specificity: do methyl-binding proteins alone provide the required specificity or are other systems involved? Precision editing and an improved understanding of m⁶A stoichiometry should help provide answers. Finally, RNA methylation has already been demonstrated to have a role in subcellular localization^{48–50}, so it is exciting to speculate that m⁶A could also mark specific RNAs for inheritance through cell divisions or even across generations, similar to what our recent preprint reports m^{6,2}A to do on 18S rRNA¹⁴¹.

These are exciting times for the field. With the rapid improvement of existing methods and development of new technology, the study of m⁶A is poised to uncover new biological regulatory systems and m⁶A may even find use as a therapeutic target¹⁴².

Acknowledgements

Work from the Greer laboratory is supported by grants from the US National Institutes of Health (NIH) (DP2AG055947 and R01AI151215). The authors apologize for literature omitted owing to space limitations.

Glossary

Hoogsteen base pairing

An alternative base pairing in which the purine is flipped and form different hydrogen bonds with partner bases. For adenines, the second hydrogen bond with the pyrimidine base is formed with N6 rather than N1. These alternative base pairs allow for additional structures beyond double helix including triplexes and quadruplexes.

miRNA microprocessor complex

A protein complex involved in the early stages of processing microRNA (miRNA) and RNA interference in animal cells.

Spliceosome

A large RNA–protein complex that catalyses the removal of introns from nuclear pre-mRNA.

Long non-coding RNAs

(lncRNAs). Non-coding RNAs longer than 200 nucleotides.

Chromosome-associated regulatory RNAs

(carRNAs). regulatory RNAs associated with the chromatin.

Endogenous retrovirus RNAs

(ERVs). The prevalent endogenous viral elements that are derived from retroviruses that have become integrated into the genome.

R-loops

These RNA:DNA hybrids form three-stranded structures when nascent RNA transcripts hybridize with one strand of the DNA template.

References

1. Wei CM, Gershowitz A & Moss B Methylated nucleotides block 5' terminus of HeLa cell messenger RNA. *Cell* 4, 379–386 (1975). [PubMed: 164293]
2. Sommer S, Lavi U & Darnell JE Jr. The absolute frequency of labeled *N*⁶-methyladenosine in HeLa cell messenger RNA decreases with label time. *J. Mol. Biol.* 124, 487–499 (1978). [PubMed: 712844]
3. Meyer KD et al. Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near stop codons. *Cell* 149, 1635–1646 (2012). [PubMed: 22608085]
4. Dominissini D et al. Topology of the human and mouse m⁶A RNA methylomes revealed by m⁶A-seq. *Nature* 485, 201–206 (2012). [PubMed: 22575960] Together with Meyer et al. (2012), this paper reports the mapping of m⁶A in the human and mouse transcriptome.
5. Tegowski M, Flamand MN & Meyer KD scDART-seq reveals distinct m⁶A signatures and mRNA methylation heterogeneity in single cells. *Mol. Cell* 82, 868–878.e10 (2022). [PubMed: 35081365]
6. Liu J et al. A METTL3–METTL14 complex mediates mammalian nuclear RNA *N*⁶-adenosine methylation. *Nat. Chem. Biol.* 10, 93–95 (2014). [PubMed: 24316715] This paper reports that the METTL3–METTL14–WTAP complex mediates *N*⁶-adenosine methylation.
7. Wei CM & Moss B Nucleotide sequences at the *N*⁶-methyladenosine sites of HeLa cell messenger ribonucleic acid. *Biochemistry* 16, 1672–1676 (1977). [PubMed: 856255]
8. Linder B et al. Single-nucleotide-resolution mapping of m⁶A and m⁶Am throughout the transcriptome. *Nat. Methods* 12, 767–772 (2015). [PubMed: 26121403]
9. Zheng G et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. *Mol. Cell* 49, 18–29 (2013). [PubMed: 23177736] This study identifies and characterizes ALKBH5 as an m⁶A demethylase, demonstrating that m⁶A is a dynamic reversible modification in mRNA.
10. Jia G et al. *N*⁶-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. *Nat. Chem. Biol.* 7, 885–887 (2011). [PubMed: 22002720] This study identifies and characterizes FTO as an m⁶A demethylase, suggesting that m⁶A is a dynamic reversible modification in mRNA; it should be read in conjunction with Mauer et al. (2017), which suggests that FTO is an m⁶Am demethylase.

11. Piekna-Przybylska D, Decatur WA & Fournier MJ The 3D rRNA modification maps database: with interactive tools for ribosome analysis. *Nucleic Acids Res.* 36, D178–D183 (2008). [PubMed: 17947322]
12. Sergiev PV, Aleksashin NA, Chugunova AA, Polikanov YS & Dontsova OA Structural and evolutionary insights into ribosomal RNA methylation. *Nat. Chem. Biol.* 14, 226–235 (2018). [PubMed: 29443970]
13. Ma H et al. N^6 -methyladenosine methyltransferase ZCCHC4 mediates ribosomal RNA methylation. *Nat. Chem. Biol.* 15, 88–94 (2019). [PubMed: 30531910]
14. Ren W et al. Structure and regulation of ZCCHC4 in m^6A -methylation of 28S rRNA. *Nat. Commun.* 10, 5042 (2019). [PubMed: 31695039]
15. Pinto R et al. The human methyltransferase ZCCHC4 catalyses N^6 -methyladenosine modification of 28S ribosomal RNA. *Nucleic Acids Res.* 48, 830–846 (2020). [PubMed: 31799605]
16. van Tran N et al. The human 18S rRNA m^6A methyltransferase METTL5 is stabilized by TRMT112. *Nucleic Acids Res.* 47, 7719–7733 (2019). [PubMed: 31328227]
17. Liberman N et al. N^6 -Adenosine methylation of ribosomal RNA affects lipid oxidation and stress resistance. *Sci. Adv.* 6, eaaz4370 (2020). [PubMed: 32494643]
18. Xing M et al. The 18S rRNA m^6A methyltransferase METTL5 promotes mouse embryonic stem cell differentiation. *EMBO Rep.* 21, e49863 (2020). [PubMed: 32783360]
19. Rong B et al. Ribosome 18S m^6A methyltransferase METTL5 promotes translation initiation and breast cancer cell growth. *Cell Rep.* 33, 108544 (2020). [PubMed: 33357433]
20. Leismann J et al. The 18S ribosomal RNA m^6A methyltransferase Mettl5 is required for normal walking behavior in *Drosophila*. *EMBO Rep.* 21, e49443 (2020). [PubMed: 32350990]
21. Ignatova VV et al. The rRNA m^6A methyltransferase METTL5 is involved in pluripotency and developmental programs. *Genes Dev.* 34, 715–729 (2020). [PubMed: 32217665]
22. Sendinc E, Valle-Garcia D, Jiao A & Shi Y Analysis of m^6A RNA methylation in *Caenorhabditis elegans*. *Cell Discov.* 6, 47 (2020). [PubMed: 32695436]
23. Sepich-Poore C et al. The METTL5–TRMT112 N^6 -methyladenosine methyltransferase complex regulates mRNA translation via 18S rRNA methylation. *J. Biol. Chem.* 298, 101590 (2022). [PubMed: 35033535]
24. Kierzek E & Kierzek R The thermodynamic stability of RNA duplexes and hairpins containing N^6 -alkyladenosines and 2-methylthio- N^6 -alkyladenosines. *Nucleic Acids Res.* 31, 4472–4480 (2003). [PubMed: 12888507]
25. Meyer KD & Jaffrey SR The dynamic epitranscriptome: N^6 -methyladenosine and gene expression control. *Nat. Rev.* 15, 313–326 (2014).
26. Liu N et al. N^6 -methyladenosine-dependent RNA structural switches regulate RNA–protein interactions. *Nature* 518, 560–564 (2015). [PubMed: 25719671] This paper describes a mechanism by which m^6A affects RNA folding to indirectly have an impact on the binding of proteins to RNA.
27. Wang S et al. The m^6A methylation perturbs the Hoogsteen pairing-guided incorporation of an oxidized nucleotide. *Chem. Sci.* 8, 6380–6388 (2017). [PubMed: 29308175]
28. Ashraf S, Huang L & Lilley DMJ Effect of methylation of adenine N^6 on kink turn structure depends on location. *RNA Biol.* 16, 1377–1385 (2019). [PubMed: 31234702]
29. Ogawa A et al. N^6 -methyladenosine (m^6A) is an endogenous A3 adenosine receptor ligand. *Mol. Cell* 81, 659–674.e7 (2021). [PubMed: 33472058]
30. Patil DP, Pickering BF & Jaffrey SR Reading m^6A in the transcriptome: m^6A -binding proteins. *Trends Cell Biol.* 28, 113–127 (2018). [PubMed: 29103884]
31. Shi H, Wei J & He C Where, when, and how: context-dependent functions of RNA methylation writers, readers, and erasers. *Mol. Cell* 74, 640–650 (2019). [PubMed: 31100245]
32. Zaccara S, Ries RJ & Jaffrey SR Reading, writing and erasing mRNA methylation. *Nat. Rev.* 20, 608–624 (2019).
33. Huang H et al. Recognition of RNA N^6 -methyladenosine by IGF2BP proteins enhances mRNA stability and translation. *Nat. Cell Biol.* 20, 285–295 (2018). [PubMed: 29476152]

34. Edupuganti RR et al. N^6 -methyladenosine (m^6A) recruits and repels proteins to regulate mRNA homeostasis. *Nat. Struct. Mol. Biol* 24, 870–878 (2017). [PubMed: 28869609]
35. Ping XL et al. Mammalian WTAP is a regulatory subunit of the RNA N^6 -methyladenosine methyltransferase. *Cell Res.* 24, 177–189 (2014). [PubMed: 24407421]
36. Fustin JM et al. RNA-methylation-dependent RNA processing controls the speed of the circadian clock. *Cell* 155, 793–806 (2013). [PubMed: 24209618]
37. Meyer KD et al. 5' UTR m^6A promotes cap-independent translation. *Cell* 163, 999–1010 (2015). [PubMed: 26593424]
38. Wang X et al. N^6 -methyladenosine modulates messenger RNA translation efficiency. *Cell* 161, 1388–1399 (2015). [PubMed: 26046440] Together with Meyer et al. (2015), this paper establishes a role for m^6A in regulating mRNA translation.
39. Zhou J et al. Dynamic m^6A mRNA methylation directs translational control of heat shock response. *Nature* 526, 591–594 (2015). [PubMed: 26458103]
40. Li A et al. Cytoplasmic m^6A reader YTHDF3 promotes mRNA translation. *Cell Res.* 27, 444–447 (2017). [PubMed: 28106076]
41. Wang X et al. N^6 -methyladenosine-dependent regulation of messenger RNA stability. *Nature* 505, 117–120 (2014). [PubMed: 24284625] This paper establishes a role for m^6A in modulating mRNA stability.
42. Viegas IJ et al. N^6 -methyladenosine in poly(A) tails stabilize VSG transcripts. *Nature* 604, 362–370 (2022). [PubMed: 35355019]
43. Alarcon CR, Lee H, Goodarzi H, Halberg N & Tavazoie SF N^6 -methyladenosine marks primary microRNAs for processing. *Nature* 519, 482–485 (2015). [PubMed: 25799998] This paper establishes a role for m^6A in modulating miRNA processing.
44. Alarcon CR et al. HNRNPA2B1 is a mediator of m^6A -dependent nuclear RNA processing events. *Cell* 162, 1299–1308 (2015). [PubMed: 26321680]
45. Lence T et al. m^6A modulates neuronal functions and sex determination in *Drosophila*. *Nature* 540, 242–247 (2016). [PubMed: 27919077]
46. Haussmann IU et al. m^6A potentiates Sxl alternative pre-mRNA splicing for robust *Drosophila* sex determination. *Nature* 540, 301–304 (2016). [PubMed: 27919081]
47. Xiao W et al. Nuclear m^6A reader YTHDC1 regulates mRNA splicing. *Mol. Cell* 61, 507–519 (2016). [PubMed: 26876937] This study establishes a role for m^6A in modulating splicing.
48. Roundtree IA et al. YTHDC1 mediates nuclear export of N^6 -methyladenosine methylated mRNAs. *eLife* 6, e31311 (2017). [PubMed: 28984244]
49. Edens BM et al. FMRP modulates neural differentiation through m^6A -dependent mRNA nuclear export. *Cell Rep.* 28, 845–854.e5 (2019). [PubMed: 31340148]
50. Hsu PJ et al. The RNA-binding protein FMRP facilitates the nuclear export of N^6 -methyladenosine-containing mRNAs. *J. Biol. Chem* 294, 19889–19895 (2019). [PubMed: 31753916]
51. Wang Y et al. N^6 -methyladenosine modification destabilizes developmental regulators in embryonic stem cells. *Nat. Cell Biol* 16, 191–198 (2014). [PubMed: 24394384] This study establishes a role for METTL3 and METTL14 in stemcell renewal via reduced stability of m^6A -modified transcripts.
52. Du H et al. YTHDF2 destabilizes m^6A -containing RNA through direct recruitment of the CCR4–NOT deadenylase complex. *Nat. Commun* 7, 12626 (2016). [PubMed: 27558897]
53. Park OH et al. Endoribonucleolytic cleavage of m^6A -containing RNAs by RNase P/MRP complex. *Mol. Cell* 74, 494–507.e8 (2019). [PubMed: 30930054]
54. Shi H et al. YTHDF3 facilitates translation and decay of N^6 -methyladenosine-modified RNA. *Cell Res.* 27, 315–328 (2017). [PubMed: 28106072]
55. Choi J et al. N^6 -methyladenosine in mRNA disrupts tRNA selection and translation-elongation dynamics. *Nat. Struct. Mol. Biol* 23, 110–115 (2016). [PubMed: 26751643]
56. Taoka M et al. Landscape of the complete RNA chemical modifications in the human 80S ribosome. *Nucleic Acids Res.* 46, 9289–9298 (2018). [PubMed: 30202881]

57. Chen T et al. m⁶A RNA methylation is regulated by microRNAs and promotes reprogramming to pluripotency. *Cell Stem Cell* 16, 289–301 (2015). [PubMed: 25683224]
58. Das Mandal S & Ray PS Transcriptome-wide analysis reveals spatial correlation between N⁶-methyladenosine and binding sites of microRNAs and RNA-binding proteins. *Genomics* 113, 205–216 (2021). [PubMed: 33340693]
59. Kanoria S, Rennie WA, Carmack CS, Lu J & Ding Y N⁶-methyladenosine enhances post-transcriptional gene regulation by microRNAs. *Bioinform Adv.* 2, vbab046 (2022). [PubMed: 35098135]
60. Chen LL The expanding regulatory mechanisms and cellular functions of circular RNAs. *Nat. Rev* 21, 475–490 (2020).
61. Memczak S et al. Circular RNAs are a large class of animal RNAs with regulatory potency. *Nature* 495, 333–338 (2013). [PubMed: 23446348]
62. Hansen TB et al. Natural RNA circles function as efficient microRNA sponges. *Nature* 495, 384–388 (2013). [PubMed: 23446346]
63. Yang Y et al. Extensive translation of circular RNAs driven by N⁶-methyladenosine. *Cell Res.* 27, 626–641 (2017). [PubMed: 28281539]
64. Di Timoteo G et al. Modulation of circRNA metabolism by m⁶A modification. *Cell Rep.* 31, 107641 (2020). [PubMed: 32402287]
65. Pendleton KE et al. The U6 snRNA m⁶A methyltransferase METTL16 regulates SAM synthetase intron retention. *Cell* 169, 824–835.e14 (2017). [PubMed: 28525753] This study shows that METTL16 m⁶A methyltransferase regulates SAM synthetase mRNA splicing, modulating SAM levels and, thereby, indirectly regulating the methylation of proteins and nucleic acids.
66. Warda AS et al. Human METTL16 is a N⁶-methyladenosine (m⁶A) methyltransferase that targets pre-mRNAs and various non-coding RNAs. *EMBO Rep.* 18, 2004–2014 (2017). [PubMed: 29051200]
67. Huang H et al. Histone H3 trimethylation at lysine 36 guides m⁶A RNA modification co-transcriptionally. *Nature* 567, 414–419 (2019). [PubMed: 30867593]
68. Li Y et al. N⁶-methyladenosine co-transcriptionally directs the demethylation of histone H3K9me2. *Nat. Genet* 52, 870–877 (2020). [PubMed: 32778823]
69. Akhtar J et al. m⁶A RNA methylation regulates promoter-proximal pausing of RNA polymerase II. *Mol. Cell* 81, 3356–3367.e6 (2021). [PubMed: 34297910]
70. Xu W et al. Dynamic control of chromatin-associated m⁶A methylation regulates nascent RNA synthesis. *Mol. Cell* 82, 1156–1168.e7 (2022). [PubMed: 35219383]
71. Mendel M et al. Methylation of structured RNA by the m⁶A writer METTL16 is essential for mouse embryonic development. *Mol. Cell* 71, 986–1000.e11 (2018). [PubMed: 30197299]
72. Mendel M et al. Splice site m⁶A methylation prevents binding of U2AF35 to inhibit RNA splicing. *Cell* 184, 3125–3142.e25 (2021). [PubMed: 33930289]
73. Yang L, Froberg JE & Lee JT Long noncoding RNAs: fresh perspectives into the RNA world. *Trends Biochem. Sci* 39, 35–43 (2014). [PubMed: 24290031]
74. Patil DP et al. m⁶A RNA methylation promotes XIST-mediated transcriptional repression. *Nature* 537, 369–373 (2016). [PubMed: 27602518] This paper establishes a role for m⁶A in *Xist*-mediated silencing.
75. Nesterova TB et al. Systematic allelic analysis defines the interplay of key pathways in X chromosome inactivation. *Nat. Commun* 10, 3129 (2019). [PubMed: 31311937]
76. Kopp F & Mendell JT Functional classification and experimental dissection of long noncoding RNAs. *Cell* 172, 393–407 (2018). [PubMed: 29373828]
77. Wang X et al. N⁶-methyladenosine modification of MALAT1 promotes metastasis via reshaping nuclear speckles. *Dev. Cell* 56, 702–715.e8 (2021). [PubMed: 33609462]
78. Andergassen D & Rinn JL From genotype to phenotype: genetics of mammalian long non-coding RNAs in vivo. *Nat. Rev. Genet* 23, 229–243 (2022). [PubMed: 34837040]
79. Liu J et al. N⁶-methyladenosine of chromosome-associated regulatory RNA regulates chromatin state and transcription. *Science* 367, 580–586 (2020). [PubMed: 31949099] This study performs targeted epigenomic editing to test the direct role of m⁶A on specific RNAs.

80. Lee JH et al. Enhancer RNA m⁶A methylation facilitates transcriptional condensate formation and gene activation. *Mol. Cell* 81, 3368–3385.e9 (2021). [PubMed: 34375583]
81. Romanish MT, Cohen CJ & Mager DL Potential mechanisms of endogenous retroviral-mediated genomic instability in human cancer. *Semin. Cancer Biol* 20, 246–253 (2010). [PubMed: 20685251]
82. Chelmicki T et al. m⁶A RNA methylation regulates the fate of endogenous retroviruses. *Nature* 591, 312–316 (2021). [PubMed: 33442060] This study establishes a role for m⁶A in suppressing ERVs to help maintain genome stability.
83. Xu W et al. METTL3 regulates heterochromatin in mouse embryonic stem cells. *Nature* 591, 317–321 (2021). [PubMed: 33505026]
84. Niehrs C & Luke B Regulatory R-loops as facilitators of gene expression and genome stability. *Nat. Rev* 21, 167–178 (2020).
85. Abakir A et al. N⁶-methyladenosine regulates the stability of RNA:DNA hybrids in human cells. *Nat. Genet* 52, 48–55 (2020). [PubMed: 31844323] This paper establishes a role for m⁶A in regulating R-loop formation.
86. Yang X et al. m⁶A promotes R-loop formation to facilitate transcription termination. *Cell Res.* 29, 1035–1038 (2019). [PubMed: 31606733]
87. Zhang C et al. METTL3 and N⁶-methyladenosine promote homologous recombination-mediated repair of DSBs by modulating DNA–RNA hybrid accumulation. *Mol. Cell* 79, 425–442.e7 (2020). [PubMed: 32615088]
88. Geula S et al. Stem cells. m⁶A mRNA methylation facilitates resolution of naive pluripotency toward differentiation. *Science* 347, 1002–1006 (2015). [PubMed: 25569111] This paper establishes a role for METTL3 in mES cell renewal and differentiation and shows that m⁶A reduces pluripotency factor transcript stability to facilitate ES cell differentiation.
89. Meng TG et al. Mettl14 is required for mouse postimplantation development by facilitating epiblast maturation. *FASEB J.* 33, 1179–1187 (2019). [PubMed: 30110177]
90. Zhong S et al. MTA is an *Arabidopsis* messenger RNA adenosine methylase and interacts with a homolog of a sex-specific splicing factor. *Plant. Cell* 20, 1278–1288 (2008). [PubMed: 18505803]
91. Batista PJ et al. m⁶A RNA modification controls cell fate transition in mammalian embryonic stem cells. *Cell Stem Cell* 15, 707–719 (2014). [PubMed: 25456834]
92. Aguilo F et al. Coordination of m⁶A mRNA methylation and gene transcription by ZFP217 regulates pluripotency and reprogramming. *Cell Stem Cell* 17, 689–704 (2015). [PubMed: 26526723]
93. Wen J et al. Zc3h13 regulates nuclear RNA m⁶A methylation and mouse embryonic stem cell self-renewal. *Mol. Cell* 69, 1028–1038.e6 (2018). [PubMed: 29547716]
94. Bertero A et al. The SMAD2/3 interactome reveals that TGFβ controls m⁶A mRNA methylation in pluripotency. *Nature* 555, 256–259 (2018). [PubMed: 29489750]
95. Heck AM, Russo J, Wilusz J, Nishimura EO & Wilusz CJ YTHDF2 destabilizes m⁶A-modified neural-specific RNAs to restrain differentiation in induced pluripotent stem cells. *RNA* 26, 739–755 (2020). [PubMed: 32169943]
96. Zaccara S & Jaffrey SR A unified model for the function of YTHDF proteins in regulating m⁶A-modified mRNA. *Cell* 181, 1582–1595.e18 (2020). [PubMed: 32492408]
97. Yartseva V & Giraldez AJ The maternal-to-zygotic transition during vertebrate development: a model for reprogramming. *Curr. Top. Dev. Biol* 113, 191–232 (2015). [PubMed: 26358874]
98. Zhao BS et al. m⁶A-dependent maternal mRNA clearance facilitates zebrafish maternal-to-zygotic transition. *Nature* 542, 475–478 (2017). [PubMed: 28192787] This study establishes a role for m⁶A in maternal transcript clearance during zebrafish MZT.
99. Kontur C, Jeong M, Cifuentes D & Giraldez AJ Ythdf m⁶A readers function redundantly during zebrafish development. *Cell Rep.* 33, 108598 (2020). [PubMed: 33378672]
100. Wojtas MN et al. Regulation of m⁶A transcripts by the 3′ → 5′ RNA helicase YTHDC2 is essential for a successful meiotic program in the mammalian germline. *Mol. Cell* 68, 374–387.e12 (2017). [PubMed: 29033321]
101. Hsu PJ et al. Ythdc2 is an N⁶-methyladenosine binding protein that regulates mammalian spermatogenesis. *Cell Res.* 27, 1115–1127 (2017). [PubMed: 28809393]

102. Bailey AS et al. The conserved RNA helicase YTHDC2 regulates the transition from proliferation to differentiation in the germline. *eLife* 6, e26116 (2017). [PubMed: 29087293]
103. Ivanova I et al. The RNA m⁶A reader YTHDF2 is essential for the post-transcriptional regulation of the maternal transcriptome and oocyte competence. *Mol. Cell* 67, 1059–1067.e4 (2017). [PubMed: 28867294]
104. Kasowitz SD et al. Nuclear m⁶A reader YTHDC1 regulates alternative polyadenylation and splicing during mouse oocyte development. *PLoS Genet.* 14, e1007412 (2018). [PubMed: 29799838]
105. Sui X et al. METTL3-mediated m⁶A is required for murine oocyte maturation and maternal-to-zygotic transition. *Cell Cycle* 19, 391–404 (2020). [PubMed: 31916488]
106. Giraldez AJ et al. Zebrafish miR-430 promotes deadenylation and clearance of maternal mRNAs. *Science* 312, 75–79 (2006). [PubMed: 16484454]
107. Chang H et al. Terminal uridylyltransferases execute programmed clearance of maternal transcriptome in vertebrate embryos. *Mol. Cell* 70, 72–82.e7 (2018). [PubMed: 29625039]
108. Wu Y & Hirschi KK Regulation of hemogenic endothelial cell development and function. *Annu. Rev. Physiol* 83, 17–37 (2021). [PubMed: 33035429]
109. Zhang C et al. m⁶A modulates haematopoietic stem and progenitor cell specification. *Nature* 549, 273–276 (2017). [PubMed: 28869969]
110. Lv J et al. Endothelial-specific m⁶A modulates mouse hematopoietic stem and progenitor cell development via Notch signaling. *Cell Res.* 28, 249–252 (2018). [PubMed: 29148543]
111. Lee H et al. Stage-specific requirement for Mettl3-dependent m⁶A mRNA methylation during haematopoietic stem cell differentiation. *Nat. Cell Biol* 21, 700–709 (2019). [PubMed: 31061465]
112. Vu LP et al. The N⁶-methyladenosine (m⁶A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. *Nat. Med* 23, 1369–1376 (2017). [PubMed: 28920958]
113. Weng H et al. METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m⁶A modification. *Cell Stem Cell* 22, 191–205.e9 (2018). [PubMed: 29290617]
114. Yoon KJ et al. Temporal control of mammalian cortical neurogenesis by m⁶A methylation. *Cell* 171, 877–889.e17 (2017). [PubMed: 28965759]
115. Wang Y et al. N⁶-methyladenosine RNA modification regulates embryonic neural stem cell self-renewal through histone modifications. *Nat. Neurosci* 21, 195–206 (2018). [PubMed: 29335608]
116. Li M et al. Ythdf2-mediated m⁶A mRNA clearance modulates neural development in mice. *Genome Biol.* 19, 69 (2018). [PubMed: 29855337]
117. Li L et al. Fat mass and obesity-associated (FTO) protein regulates adult neurogenesis. *Hum. Mol. Genet* 26, 2398–2411 (2017). [PubMed: 28398475]
118. Liu J, Harada BT & He C Regulation of gene expression by N⁶-methyladenosine in cancer. *Trends Cell Biol.* 29, 487–499 (2019). [PubMed: 30940398]
119. Yang C et al. The role of m⁶A modification in physiology and disease. *Cell Death Dis.* 11, 960 (2020). [PubMed: 33162550]
120. Buffington SA, Huang W & Costa-Mattioli M Translational control in synaptic plasticity and cognitive dysfunction. *Annu. Rev. Neurosci* 37, 17–38 (2014). [PubMed: 25032491]
121. Merkurjev D et al. Synaptic N⁶-methyladenosine (m⁶A) epitranscriptome reveals functional partitioning of localized transcripts. *Nat. Neurosci* 21, 1004–1014 (2018). [PubMed: 29950670] This paper reports the identification of subcellular synapse-specific m⁶A-methylated transcripts.
122. Yu J et al. Dynamic m⁶A modification regulates local translation of mRNA in axons. *Nucleic Acids Res.* 46, 1412–1423 (2018). [PubMed: 29186567]
123. Widagdo J et al. Experience-dependent accumulation of N⁶-methyladenosine in the prefrontal cortex is associated with memory processes in mice. *J. Neurosci* 36, 6771–6777 (2016). [PubMed: 27335407]

124. Walters BJ et al. The role of the RNA demethylase FTO (fat mass and obesity-associated) and mRNA methylation in hippocampal memory formation. *Neuropsychopharmacology* 42, 1502–1510 (2017). [PubMed: 28205605]
125. Engel M et al. The role of m⁶A/m-RNA methylation in stress response regulation. *Neuron* 99, 389–403.e9 (2018). [PubMed: 30048615]
126. Mauer J et al. Reversible methylation of m⁶Am in the 5' cap controls mRNA stability. *Nature* 541, 371–375 (2017). [PubMed: 28002401] This study characterizes FTO as an m⁶Am demethylase that regulates mRNA stability, suggesting that m⁶Am is a dynamic reversible modification; it should be read in conjunction with Jia et al. (2011), which suggests that FTO is a m⁶A demethylase.
127. Zhang Z et al. METTL3-mediated N⁶-methyladenosine mRNA modification enhances long-term memory consolidation. *Cell Res.* 28, 1050–1061 (2018). [PubMed: 30297870]
128. Shi H et al. m⁶A facilitates hippocampus-dependent learning and memory through YTHDF1. *Nature* 563, 249–253 (2018). [PubMed: 30401835] This study reveals a regulatory role for m⁶A in neurobehavioural phenotypes by promoting translation of selected transcripts.
129. Li HB et al. m⁶A mRNA methylation controls T cell homeostasis by targeting the IL-7/STAT5/SOCS pathways. *Nature* 548, 338–342 (2017). [PubMed: 28792938]
130. Winkler R et al. m⁶A modification controls the innate immune response to infection by targeting type I interferons. *Nat. Immunol* 20, 173–182 (2019). [PubMed: 30559377]
131. Liu Y et al. N⁶-methyladenosine RNA modification-mediated cellular metabolism rewiring inhibits viral replication. *Science* 365, 1171–1176 (2019). [PubMed: 31439758] This paper shows that m⁶A-marked transcripts allow a levelled response to viral infection.
132. Chow KT, Gale M Jr & Loo YM RIG-I and other RNA sensors in antiviral immunity. *Annu. Rev. Immunol* 36, 667–694 (2018). [PubMed: 29677479]
133. Lu M et al. N⁶-methyladenosine modification enables viral RNA to escape recognition by RNA sensor RIG-I. *Nat. Microbiol* 5, 584–598 (2020). [PubMed: 32015498]
134. Qiu W et al. N⁶-methyladenosine RNA modification suppresses antiviral innate sensing pathways via reshaping double-stranded RNA. *Nat. Commun* 12, 1582 (2021). [PubMed: 33707441]
135. Chen YG et al. N⁶-methyladenosine modification controls circular RNA immunity. *Mol. Cell* 76, 96–109.e9 (2019). [PubMed: 31474572]
136. Su R et al. R-2HG exhibits anti-tumor activity by targeting FTO/m⁶A/MYC/CEBPA signaling. *Cell* 172, 90–105.e23 (2018). [PubMed: 29249359]
137. Paris J et al. Targeting the RNA m⁶A reader YTHDF2 selectively compromises cancer stem cells in acute myeloid leukemia. *Cell Stem Cell* 25, 137–148.e6 (2019). [PubMed: 31031138]
138. Cheng Y et al. N⁶-methyladenosine on mRNA facilitates a phase-separated nuclear body that suppresses myeloid leukemic differentiation. *Cancer Cell* 39, 958–972.e8 (2021). [PubMed: 34048709]
139. Cui Q et al. m⁶A RNA methylation regulates the self-renewal and tumorigenesis of glioblastoma stem cells. *Cell Rep.* 18, 2622–2634 (2017). [PubMed: 28297667]
140. Zhang S et al. m⁶A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program. *Cancer Cell* 31, 591–606.e6 (2017). [PubMed: 28344040]
141. Liberman N et al. Intergenerational hormesis is regulated by heritable 18S rRNA methylation. Preprint at bioRxiv 10.1101/2021/1109.1127.461965 (2021).
142. Yankova E et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. *Nature* 593, 597–601 (2021). [PubMed: 33902106] This study identifies small molecules that can effectively inhibit METTL3, raising the possibility of therapeutic options for myeloid leukaemia and other m⁶A-related pathologies.
143. Kruse S et al. A novel synthesis and detection method for cap-associated adenosine modifications in mouse mRNA. *Sci. Rep* 1, 126 (2011). [PubMed: 22355643]
144. Yuki H, Kawasaki H, Imayuki A & Yajima T Determination of 6-methyladenine in DNA by high-performance liquid chromatography. *J. Chromatogr* 168, 489–494 (1979). [PubMed: 216706]
145. Thuring K, Schmid K, Keller P & Helm M LC-MS analysis of methylated RNA. *Methods Mol. Biol* 1562, 3–18 (2017). [PubMed: 28349450]

146. Liu N et al. Probing N^6 -methyladenosine RNA modification status at single nucleotide resolution in mRNA and long noncoding RNA. *RNA* 19, 1848–1856 (2013). [PubMed: 24141618]
147. Imanishi M, Tsuji S, Suda A & Futaki S Detection of N^6 -methyladenosine based on the methyl-sensitivity of MazF RNA endonuclease. *Chem. Commun* 53, 12930–12933 (2017).
148. Garcia-Campos MA et al. Deciphering the “ m^6A code” via antibody-independent quantitative profiling. *Cell* 178, 731–747.e16 (2019). [PubMed: 31257032]
149. Dominissini D et al. The dynamic N^1 -methyladenosine methylome in eukaryotic messenger RNA. *Nature* 530, 441–446 (2016). [PubMed: 26863196]
150. Li X et al. Transcriptome-wide mapping reveals reversible and dynamic N^1 -methyladenosine methylome. *Nat. Chem. Biol* 12, 311–316 (2016). [PubMed: 26863410]
151. Safra M et al. The m^1A landscape on cytosolic and mitochondrial mRNA at single-base resolution. *Nature* 551, 251–255 (2017). [PubMed: 29072297]
152. Li X et al. Base-resolution mapping reveals distinct m^1A methylome in nuclear- and mitochondrial-encoded transcripts. *Mol. Cell* 68, 993–1005.e9 (2017). [PubMed: 29107537]
153. Grozhik AV et al. Antibody cross-reactivity accounts for widespread appearance of m^1A in 5' UTRs. *Nat. Commun* 10, 5126 (2019). [PubMed: 31719534]
154. Harcourt EM, Ehrenschwender T, Batista PJ, Chang HY & Kool ET Identification of a selective polymerase enables detection of N^6 -methyladenosine in RNA. *J. Am. Chem. Soc* 135, 19079–19082 (2013). [PubMed: 24328136]
155. Hong T et al. Precise antibody-independent m^6A identification via 4SedTTP-involved and FTO-assisted strategy at single-nucleotide resolution. *J. Am. Chem. Soc* 140, 5886–5889 (2018). [PubMed: 29489347]
156. Aschenbrenner J et al. Engineering of a DNA polymerase for direct m^6A sequencing. *Angew. Chem. Int. Ed* 57, 417–421 (2018).
157. Ke S et al. A majority of m^6A residues are in the last exons, allowing the potential for 3' UTR regulation. *Genes Dev.* 29, 2037–2053 (2015). [PubMed: 26404942]
158. Molinie B et al. m^6A -LAIC-seq reveals the census and complexity of the m^6A epitranscriptome. *Nat. Methods* 13, 692–698 (2016). [PubMed: 27376769]
159. Bringmann P & Luhrmann R Antibodies specific for N^6 -methyladenosine react with intact snRNPs U2 and U4/U6. *FEBS Lett.* 213, 309–315 (1987). [PubMed: 2951275]
160. Dai Q et al. NM-seq maps 2'-O-methylation sites in human mRNA with base precision. *Nat. Methods* 14, 695–698 (2017). [PubMed: 28504680]
161. Castellanos-Rubio A et al. A novel RT-QPCR-based assay for the relative quantification of residue specific m^6A RNA methylation. *Sci. Rep* 9, 4220 (2019). [PubMed: 30862814]
162. Flusberg BA et al. Direct detection of DNA methylation during single-molecule, real-time sequencing. *Nat. Methods* 7, 461–465 (2010). [PubMed: 20453866]
163. Garalde DR et al. Highly parallel direct RNA sequencing on an array of nanopores. *Nat. Methods* 15, 201–206 (2018). [PubMed: 29334379]
164. Chen Y et al. Study of the whole genome, methylome and transcriptome of *Cordyceps militaris*. *Sci. Rep* 9, 898 (2019). [PubMed: 30696919]
165. Pratanwanich PN et al. Identification of differential RNA modifications from nanopore direct RNA sequencing with xPore. *Nat. Biotechnol* 39, 1394–1402 (2021). [PubMed: 34282325]
166. Mikutis S et al. meCLICK-Seq, a substrate-hijacking and RNA degradation strategy for the study of RNA microsoftethylation. *ACS Cent. Sci* 6, 2196–2208 (2020). [PubMed: 33376781]
167. Liu W et al. Identification of a selective DNA ligase for accurate recognition and ultrasensitive quantification of N^6 -methyladenosine in RNA at one-nucleotide resolution. *Chem. Sci* 9, 3354–3359 (2018). [PubMed: 29780465]
168. Xiao Y et al. An elongation- and ligation-based qPCR amplification method for the radiolabeling-free detection of locus-specific N^6 -methyladenosine modification. *Angew. Chem. Int. Ed* 57, 15995–16000 (2018).
169. Bokar JA, Shambaugh ME, Polayes D, Matera AG & Rottman FM Purification and cDNA cloning of the AdoMet-binding subunit of the human mRNA (N^6 -adenosine)-methyltransferase.

- RNA 3, 1233–1247 (1997). [PubMed: 9409616] This paper identifies METTL3 as the catalytic subunit of the complex that mediates N^6 -adenosine methylation.
170. Clancy MJ, Shambaugh ME, Timpte CS & Bokar JA Induction of sporulation in *Saccharomyces cerevisiae* leads to the formation of N^6 -methyladenosine in mRNA: a potential mechanism for the activity of the *IME4* gene. *Nucleic Acids Res.* 30, 4509–4518 (2002). [PubMed: 12384598]
 171. Shima H et al. *S*-Adenosylmethionine synthesis is regulated by selective N^6 -adenosine methylation and mRNA degradation involving METTL16 and YTHDC1. *Cell Rep.* 21, 3354–3363 (2017). [PubMed: 29262316]
 172. Akichika S et al. Cap-specific terminal N^6 -methylation of RNA by an RNA polymerase II-associated methyltransferase. *Science* 363, eaav0080 (2019). [PubMed: 30467178]
 173. Sun H, Zhang M, Li K, Bai D & Yi C Cap-specific, terminal N^6 -methylation by a mammalian m^6Am methyltransferase. *Cell Res.* 29, 80–82 (2019). [PubMed: 30487554]
 174. Boulias K et al. Identification of the m^6Am methyltransferase PCIF1 reveals the location and functions of m^6Am in the transcriptome. *Mol. Cell* 75, 631–643.e8 (2019). [PubMed: 31279658]
 175. Sendinc E et al. PCIF1 catalyzes m^6Am mRNA methylation to regulate gene expression. *Mol. Cell* 75, 620–630.e9 (2019). [PubMed: 31279659]
 176. Belanger F, Stepinski J, Darzynkiewicz E & Pelletier J Characterization of hMTr1, a human Cap1 2'-*O*-ribose methyltransferase. *J. Biol. Chem* 285, 33037–33044 (2010). [PubMed: 20713356]
 177. Tollervey D, Lehtonen H, Jansen R, Kern H & Hurt EC Temperature-sensitive mutations demonstrate roles for yeast fibrillar in pre-rRNA processing, pre-rRNA methylation, and ribosome assembly. *Cell* 72, 443–457 (1993). [PubMed: 8431947]
 178. Kiss-Laszlo Z, Henry Y, Bachellerie JP, Caizergues-Ferrer M & Kiss T Site-specific ribose methylation of preribosomal RNA: a novel function for small nucleolar RNAs. *Cell* 85, 1077–1088 (1996). [PubMed: 8674114]
 179. Nicoloso M, Qu LH, Michot B & Bachellerie JP Intron-encoded, antisense small nucleolar RNAs: the characterization of nine novel species points to their direct role as guides for the 2'-*O*-ribose methylation of rRNAs. *J. Mol. Biol* 260, 178–195 (1996). [PubMed: 8764399]
 180. Tycowski KT, Smith CM, Shu MD & Steitz JA A small nucleolar RNA requirement for site-specific ribose methylation of rRNA in *Xenopus*. *Proc. Natl Acad. Sci. USA* 93, 14480–14485 (1996). [PubMed: 8962077]
 181. Juhling F et al. tRNAdb 2009: compilation of tRNA sequences and tRNA genes. *Nucleic Acids Res* 37, D159–D162 (2009). [PubMed: 18957446]
 182. Ozanick S, Krecic A, Andersland J & Anderson JT The bipartite structure of the tRNA m^1A58 methyltransferase from *S. cerevisiae* is conserved in humans. *RNA* 11, 1281–1290 (2005). [PubMed: 16043508]
 183. Chujo T & Suzuki T Trmt61B is a methyltransferase responsible for 1-methyladenosine at position 58 of human mitochondrial tRNAs. *RNA* 18, 2269–2276 (2012). [PubMed: 23097428]
 184. Vilardo E et al. Functional characterization of the human tRNA methyltransferases TRMT10A and TRMT10B. *Nucleic Acids Res* 48, 6157–6169 (2020). [PubMed: 32392304]
 185. Vilardo E et al. A subcomplex of human mitochondrial RNase P is a bifunctional methyltransferase — extensive moonlighting in mitochondrial tRNA biogenesis. *Nucleic Acids Res* 40, 11583–11593 (2012). [PubMed: 23042678]
 186. Lafontaine D, Delcour J, Glasser AL, Desgres J & Vandenhoute J The *DIMI* gene responsible for the conserved m^6Am^6A dimethylation in the 3'-terminal loop of 18S rRNA is essential in yeast. *J. Mol. Biol* 241, 492–497 (1994). [PubMed: 8064863]
 187. Suvorov AN, van Gemen B & van Knippenberg PH Increased kasugamycin sensitivity in *Escherichia coli* caused by the presence of an inducible erythromycin resistance (*erm*) gene of *Streptococcus pyogenes*. *Mol. Gen. Genet* 215, 152–155 (1988). [PubMed: 3071738]
 188. Shen H, Stoute J & Liu KF Structural and catalytic roles of the human 18S rRNA methyltransferases DIMT1 in ribosome assembly and translation. *J. Biol. Chem* 295, 12058–12070 (2020). [PubMed: 32616653]
 189. Chen H et al. METTL4 is an snRNA m^6Am methyltransferase that regulates RNA splicing. *Cell Res* 30, 544–547 (2020). [PubMed: 31913360]

190. Goh YT, Koh CWQ, Sim DY, Roca X & Goh WSS METTL4 catalyzes m⁶Am methylation in U2 snRNA to regulate pre-mRNA splicing. *Nucleic Acids Res* 48, 9250–9261 (2020). [PubMed: 32813009]
191. Liu F et al. ALKBH1-mediated tRNA demethylation regulates translation. *Cell* 167, 816–828.e16 (2016). [PubMed: 27745969]
192. Kawarada L et al. ALKBH1 is an RNA dioxygenase responsible for cytoplasmic and mitochondrial tRNA modifications. *Nucleic Acids Res* 45, 7401–7415 (2017). [PubMed: 28472312]
193. Aas PA et al. Human and bacterial oxidative demethylases repair alkylation damage in both RNA and DNA. *Nature* 421, 859–863 (2003). [PubMed: 12594517]
194. Xu C et al. Structural basis for selective binding of m⁶A RNA by the YTHDC1 YTH domain. *Nat. Chem. Biol* 10, 927–929 (2014). [PubMed: 25242552]
195. Theler D, Dominguez C, Blatter M, Boudet J & Allain FH Solution structure of the YTH domain in complex with N⁶-methyladenosine RNA: a reader of methylated RNA. *Nucleic Acids Res* 42, 13911–13919 (2014). [PubMed: 25389274]
196. Xu C et al. Structural basis for the discriminative recognition of N⁶-methyladenosine RNA by the human YT521-B homology domain family of proteins. *J. Biol. Chem* 290, 24902–24913 (2015). [PubMed: 26318451]
197. Liu N et al. N⁶-methyladenosine alters RNA structure to regulate binding of a low-complexity protein. *Nucleic Acids Res* 45, 6051–6063 (2017). [PubMed: 28334903]
198. Toh SM, Xiong L, Bae T & Mankin AS The methyltransferase YfgB/RlmN is responsible for modification of adenosine 2503 in 23S rRNA. *RNA* 14, 98–106 (2008). [PubMed: 18025251]
199. Furuichi Y et al. Methylated, blocked 5 termini in HeLa cell mRNA. *Proc. Natl Acad. Sci. USA* 72, 1904–1908 (1975). [PubMed: 1057180]
200. Oerum S, Degut C, Barraud P & Tisne C m¹A post-transcriptional modification in tRNAs. *Biomolecules* 7, 20 (2017). [PubMed: 28230814]
201. Peifer C et al. Yeast Rrp8p, a novel methyltransferase responsible for m¹A 645 base modification of 25S rRNA. *Nucleic Acids Res* 41, 1151–1163 (2013). [PubMed: 23180764]
202. Waku T et al. NML-mediated rRNA base methylation links ribosomal subunit formation to cell proliferation in a p53-dependent manner. *J. Cell Sci* 129, 2382–2393 (2016). [PubMed: 27149924]
203. Yokoyama W et al. rRNA adenine methylation requires T07A9.8 gene as rram-1 in *Caenorhabditis elegans*. *J. Biochem* 163, 465–474 (2018). [PubMed: 29385568]
204. Sharma S et al. A single N¹-methyladenosine on the large ribosomal subunit rRNA impacts locally its structure and the translation of key metabolic enzymes. *Sci. Rep* 8, 11904 (2018). [PubMed: 30093689]
205. Schwartz S m¹A within cytoplasmic mRNAs at single nucleotide resolution: a reconciled transcriptome-wide map. *RNA* 24, 1427–1436 (2018). [PubMed: 30131402]
206. Wei C, Gershowitz A & Moss B N⁶,O²'-Dimethyladenosine a novel methylated ribonucleoside next to the 5' terminal of animal cell and virus mRNAs. *Nature* 257, 251–253 (1975). [PubMed: 1161029]
207. Keith JM, Muthukrishnan S & Moss B Effect of methylation of the N⁶ position of the penultimate adenosine of capped mRNA on ribosome binding. *J. Biol. Chem* 253, 5039–5041 (1978). [PubMed: 670177]
208. Pandey RR et al. The mammalian Cap-specific m⁶Am RNA methyltransferase PCIF1 regulates transcript levels in mouse tissues. *Cell Rep* 32, 108038 (2020). [PubMed: 32814042]
209. Ben-Haim MS et al. Dynamic regulation of N⁶,2'-O-dimethyladenosine (m⁶Am) in obesity. *Nat. Commun* 12, 7185 (2021). [PubMed: 34893620]
210. Tartell MA et al. Methylation of viral mRNA cap structures by PCIF1 attenuates the antiviral activity of interferon-β. *Proc. Natl Acad. Sci. USA* 118, e2025769118 (2021). [PubMed: 34266951]
211. Mauer J et al. FTO controls reversible m⁶Am RNA methylation during snRNA biogenesis. *Nat. Chem. Biol* 15, 340–347 (2019). [PubMed: 30778204]

212. Zorbas C et al. The human 18S rRNA base methyltransferases DIMT1L and WBSCR22-TRMT112 but not rRNA modification are required for ribosome biogenesis. *Mol. Biol. Cell* 26, 2080–2095 (2015). [PubMed: 25851604]
213. Liu K et al. Regulation of translation by methylation multiplicity of 18S rRNA. *Cell Rep* 34, 108825 (2021). [PubMed: 33691096]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Box 1 |**Functions of other adenosine methylation modifications**

Adenosines can be monomethylated in either the N1, N2 or N6 position of the nucleobase, resulting in N^1 -methyladenosine (m^1A), N^2 -methyladenosine (m^2A) or N^6 -methyladenosine (m^6A), respectively, or can be 2'-O-methylated in the ribose yielding 2'-O-methyladenosine (Am). Additionally, adenosines can be dimethylated as is the case for $N^6,2'$ -O-dimethyladenosine (m^6Am) or N^6,N^6 -dimethyladenosine ($m^{6,2}A$) (see the figure). m^2A has thus far only been identified on adenosine 2503 of the 23S ribosomal RNA (rRNA) in prokaryotes where it helps confer a fitness advantage¹⁹⁸, whereas Am (and other 2'-O-methylated bases) is prevalent on rRNAs⁵⁶ and the first and second nucleosides of mRNAs directly after the N^7 -methylguanosine (m^7G) cap^{1,199}. The other modified adenosines are discussed in more detail below.

 m^1A in tRNAs, rRnA and mRnA

m^1A is deposited by the TRM10 and TRM6/61A methyltransferases on conserved nucleosides 9, 14, 22, 57 and 58 in cytosolic and mitochondrial tRNAs to regulate structural stability and proper folding (reviewed elsewhere²⁰⁰). These methylation events are dynamic, increasing in response to glucose, and A58 can be demethylated by ALKBH1 to slow translation initiation and elongation¹⁹¹.

m^1A has also been found to be methylated by RRP8 at a conserved adenosine in the 28S rRNA (A1322) from yeast to humans, which is required for appropriate translation initiation and translation of specific sets of transcripts^{201–204}.

The presence and prevalence of m^1A in mRNAs has been highly debated. Initial m^1A -sequencing mapping studies reported m^1A to be abundant in mammalian mRNAs and enriched near start codons, and it has been proposed to regulate translation^{149,150}. However, subsequent single-nucleotide resolution mapping studies found limited m^1A in mRNAs at low stoichiometry, and its presence leads to translation repression^{151,152,205}. A study using multiple m^1A mapping techniques confirmed the very low prevalence of m^1A in mRNAs and suggested that conflicting reports were due to non-specific antibody binding¹⁵³. It has been proposed^{151,152,205} that cells may tend to avoid mRNA m^1A deposition because m^1A disrupts base pairing, which blocks translation.

 m^6Am in mRnA and snRnA


m^6Am is an abundant RNA modification, found on at least 25% of vertebrate mRNAs and certain viral RNAs, but is restricted to the first transcribed nucleotide following the m^7G cap^{206,207}. 2'-O-Methyladenosines are N^6 -methylated by PCIF1 (REFS.^{172–175}). The phenotypic consequences and effects on RNA fate of PCIF1 deletion under basal conditions seem to be minimal, and the effects on RNA fate seem to be modest and often not in agreement in different studies^{172,174,175,208}. m^6Am has been reported to enhance translation^{126,172}, inhibit translation¹⁷⁵ or promote the stability of a subset of transcripts^{126,174}. m^6Am is a dynamic modification as FTO can remove m^6Am both in vitro and in mammalian cells¹²⁶. Recently, m^6Am has been linked to obesity in mice because a high-fat diet stimulates FTO-mediated demethylation of m^6Am in selected

metabolic genes in the liver resulting in decreases in their translation²⁰⁹. Interestingly, viruses can hijack host PCIF1 to methylate viral RNAs to evade the immune system²¹⁰.

Several small nuclear RNAs (snRNAs), including the U1 and U2 snRNAs, are also m⁶Am methylated on their caps and this methylation is removed by FTO²¹¹ (FIG. 2d). Cap m⁶Am modifications in U1 and U2 snRNAs cause altered alternative splicing²¹¹. In addition, U2 snRNAs are internally N⁶,2'-O-dimethylated at adenosine 30 by METTL4, which also increases splicing^{189,190} (FIG. 2d). Future experiments are needed to determine whether these snRNA modifications communicate with each other to create an epitranscriptomic code and how adenosine methylations help determine splicing specificity.

m^{6,2}A in rRNA

m^{6,2}A occurs at two conserved adjacent adenosines of eukaryotic 18S rRNAs (1850, 1851)¹² and the consequences on rRNA function are just beginning to be deciphered. Although these methylation events have a role in the processing of 18S rRNA^{186,212}, recent reports demonstrated that 18S rRNA N⁶,N⁶-dimethylation is induced in response to sulfur starvation in yeast and mammalian cells²¹³ or starvation in *Caenorhabditis elegans*¹⁴¹, suggesting that rRNA m^{6,2}A is not constitutive and could therefore contribute to ribosome heterogeneity to facilitate the translation of unique sets of stress resistance genes. DIMT1 is the 18S rRNA N⁶,N⁶-dimethyltransferase both in vitro and in vivo^{141,186–188}. Recent work from our laboratory suggests that worms transmit elevated m^{6,2}A 18S rRNA to their naive progeny in response to starvation, which helps confer an intergenerational hormesis phenotype (whereby low exposure to a stress induces the stress response pathway and allows a more favourable response to stress in the future)¹⁴¹.






Fig. 1 |. Molecular consequences of m⁶A modification of mRNA.

a | N⁶-Adenosine methylation is a dynamic modification that occurs in the nucleus and is regulated by both a methyltransferase complex (METTL3–METTL14–WTAP) and by demethylases (FTO and ALKBH5). N⁶-Methyladenosine (m⁶A) has been implicated in regulating various nuclear and cytoplasmic processes in the mRNA life cycle, including subcellular localization, splicing (part **b**), export (part **c**), stability or degradation (part **d**) and translation (part **e**). **b** | m⁶A regulates pre-mRNA splicing by both direct and indirect mechanisms. In a direct mechanism, YTHDC1 binding to m⁶A leads to exon inclusion by blocking binding of SRSF10 and recruitment of SRSF3. In the absence of N⁶-adenosine methylation, SRSF10 binds resulting in exon skipping. In an indirect mechanism, termed an m⁶A switch, m⁶A induces a conformational change in RNA folding,

exposing a heterogeneous nuclear ribonucleoprotein C (HNRNPC) binding motif, which leads to HNRNPC recruitment and exon retention. **c** | N^6 -Adenosine methylation facilitates mRNA nuclear export. Binding of YTHDC1 to N^6 -adenosine methylated transcripts promotes export by mediating interactions with SRSF3 and nuclear export mediator NXF1. Alternatively, binding of fragile X mental retardation protein (FMRP) to m^6A facilitates export by mediating a physical association with the nuclear export protein CMR1. **d** | m^6A can promote or inhibit mRNA degradation. YTHDF2 promotes the degradation of m^6A -modified transcripts by recruiting the CCR4–NOT1 deadenylase complex. By contrast, insulin-like growth factor 2 binding proteins (IGF2BPs) bind m^6A -containing mRNAs and protect them from degradation. **e** | m^6A either promotes or slows translation depending on its location within the mRNA. If the methylated adenosine is located within the 5' untranslated region (UTR), binding of eukaryotic translation initiation factor 3 (eIF3) recruits the 43S translation initiation complex to promote cap-independent translation. If m^6A occurs in the 3' UTR, YTHDF1 or YTHDF3 will bind and stimulate translation. However, if m^6A is localized in the coding region it can slow translation elongation rates by inhibiting efficient tRNA selection. m^7G , N^7 -methylguanosine; TF, transcription factor.




Fig. 2 | Molecular consequences of m⁶A modification of non-coding RNAs.

a | N⁶-Adenosine methylation of ribosomal RNAs (rRNAs) can promote translation or specify mRNAs to be translated. ZCCHC4 N⁶-methylates adenosine 4220 in human 28S rRNA resulting in increased translation and inhibition of cell proliferation. METTL5-mediated N⁶-methylation of adenosine 1832 on human 18S rRNA seems to result in the selective increased translation of a unique sets of transcripts. **b** | N⁶-Adenosine methylation facilitates microRNA (miRNA) processing. N⁶-Methyladenosine (m⁶A) deposition on primary (pri)-miRNAs is recognized by the heterogeneous nuclear ribonucleoprotein HNRNPA2B1, which in turn facilitates their processing to precursor (pre)-miRNAs via the Drosha–DGCR8 microprocessor complex. **c** | m⁶A regulates circular RNA (circRNA) biogenesis and function. m⁶A induces back-splicing of circRNA through a YTHDC1-dependent mechanism. In addition, YTHDF3 binds to m⁶A-modified circRNAs to enhance cap-independent translation, resulting in protein synthesis from circRNA transcripts. **d** | m⁶A regulates small nuclear RNAs (snRNAs) to facilitate spliceosome assembly. METTL16-dependent m⁶A deposition on U6 snRNAs regulates spliceosome assembly or 5' splice site recognition. N⁶,2'-O-Dimethyladenosine (m⁶Am) modification of U2 snRNAs by METTL4 increases splicing whereas FTO demethylation of U2 snRNAs inhibits splicing.




Fig. 3 |. Genomic consequences of m^6A .

a | Crosstalk between N^6 -methyladenosine (m^6A) and chromatin modifications reinforces epigenetic signatures. YTHDC1 can bind to both m^6A -modified transcripts and to the histone H3 lysine 9 (H3K9) demethylase KDM3B to induce histone demethylation to reinforce chromatin accessibility in regions being actively transcribed. Moreover, methylation of H3 lysine 36 (H3K36) can recruit the METTL3–METTL14 N^6 -adenosine methylation complex to m^6A -methylate nascent transcripts in regions of active chromatin.

b | m^6A regulates activity and folding of long non-coding RNAs (lncRNAs). *Xist* lncRNA is N^6 -adenosine methylated at many locations and m^6A promotes *Xist*-mediated gene silencing and X chromosome inactivation in a YTHDC1-dependent manner. **c** | N^6 -Adenosine methylation of *MALAT1* lncRNA induces a conformational change, which leads

to heterogeneous nuclear ribonucleoprotein C (HNRNPC) binding and alterations in nuclear organization and tumorigenesis. **d** | N^6 -Adenosine methylation of chromosome-associated regulatory RNAs (carRNAs) causes their degradation via the nuclear exosome targeting complex (NEXT) complex, resulting in gene repression. **e** | m^6A facilitates endogenous retrovirus RNA (ERV) suppression by multiple mechanisms to maintain genome stability. m^6A -modified intracisternal A-particle (IAP) mRNA is bound by YTHDC1, which recruits the histone H3K9 methyltransferase SETDB1, resulting in the deposition of repressive chromatin marks. In addition, YTHDF2 binds to m^6A -modified IAP transcripts to induce degradation of IAP mRNAs. **f** | m^6A prevents genome instability caused by RNA:DNA hybrids (R-loops). N^6 -Adenosine methylation of RNA in R-loops results in YTHDF2-dependent RNA degradation, which suppresses the formation of R-loops and prevents genomic instability. m^7G , N^7 -methylguanosine; TF, transcription factor.




Fig. 4 | m^6A is a critical modification during early development and embryogenesis.

a | N^6 -Methyladenosine (m^6A) modulates embryonic stem (ES) cell renewal and differentiation. Transcripts encoding ES cell pluripotency factors, such as SOX2 and NANOG, are selectively m^6A -modified in the nucleus of naive ES cells by the METTL3–METTL14 methyltransferase complex in conjunction with the zinc-finger protein ZC3H13. m^6A -dependent degradation of pluripotency factor mRNAs drives ES cell differentiation to the primed state, whereas new m^6A deposition is inhibited by sequestration of the METTL3–METTL14 complex to the cytoplasm by the zinc-finger protein ZFP217. **b** | m^6A facilitates clearance of maternal mRNAs during the earliest developmental stages of zebrafish and mice. During zebrafish maternal-to-zygotic transition (MZT), YTHDF2 binds to m^6A -modified transcripts to direct degradation via the CCR4–NOT deadenylase complex. Binding of the microRNA mir-430 to maternal transcripts further promotes their clearance. By contrast, C5-cytosine methylation (m^5C) of maternal transcripts promotes stabilization. **c** | m^6A promotes haematopoietic stem cell (HSC) differentiation at several points in the differentiation pathway. m^6A deposition on *Myc* mRNA stimulates MYC protein synthesis, which promotes HSC differentiation to haematopoietic progenitor cells. Subsequently, m^6A -

dependent degradation of *Myc* and *Myb* transcripts drives haematopoietic progenitor cell (HPC) differentiation to the myeloid cell lineage.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Fig. 5 | m⁶A function in adult cell homeostasis in the nervous system and immune reactions.
a | In neurons, N⁶-methyladenosine (m⁶A) is proposed to regulate local translation of selected dendritic transcripts encoding proteins that facilitating memory consolidation during learning and fear conditioning, such as ARC, a synaptic protein important for fast excitatory neurotransmission. The N⁶-adenosine methyltransferase METTL3, demethylase FTO and binding proteins YTHDF1–YTHDF3, as well as m⁶A-modified transcripts, are enriched near synapses, raising the possibility of localized regulation of these transcripts.
b | m⁶A facilitates degradation of specific transcripts in immune cells to allow a rapid response to viral infection and a return to basal states once the virus has been inhibited. Viral infection induces type I interferon activation to inhibit additional viral infection and, subsequently, N⁶-adenosine methylation of mRNA encoding interferon-β (IFNβ) elicits

its decay, facilitating a return to basal IFN β levels. In macrophages, following vesicular stomatitis virus (VSV) infection, mRNA encoding 2-oxyglutarate dehydrogenase (OGDH) are *N*⁶-adenosine methylated, which causes their degradation and blocks synthesis of the naturally produced itaconate, which is an activator of VSV replication.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1 |

Techniques for detecting adenine methylation

Technique	Description	Sensitivity	Limitations	Refs.
2D TLC	RNase T1 digestion and radioactive labelling followed by 2D TLC to separate different modified bases	High relative quantification	No qualitative info	90,143
UHPLC-MS/MS	Chemical separation by UHPLC followed by detection with tandem MS/MS	Highly quantitative	Need to ensure that methylated bases are not being contributed by contaminating mycoplasma or digestion enzymes	144,145
SCARLET	RNase H site-specific cleavage, splinted ligation, p32 labelling, digestion and TLC to separate and quantify specific methylation sites.	Highly quantitative and qualitative	Only assesses one specific site per assay; the assay is laborious	146
MazF and MAZTER-seq	Site-specific fluorescent quantification of m ⁶ A found in specific context upon MazF cleavage or can be expanded to transcriptome-wide mapping by sequencing in MAZTERseq	High qualitative info, can provide stoichiometry information	Can only detect methylation in specific context of MazF cleavage sites (ACA triplet)	147,148
meRIP-seq and meKIP-qPCR	Immunoprecipitation followed by sequencing or qPCR	Medium	Depends on immunoprecipitation efficiency Not single-nucleotide resolution Can be prone to misreading other modifications (for example, m ¹ A) as m ⁶ A	3,4,51, 149–153
RT-based detection methods	Several techniques detect signatures created by RT enzymes (such as 4SedTTP-RT, Tth polymerase and RT-KTQ polymerase) that terminate reverse transcription, or incorporate an incorrect base, when they encounter m ⁶ A	Medium to low	Higher false-positive rate than other methods	154–156
m ⁶ CLIP and m ⁶ A-CLIP	Antibody crosslinking followed by sequencing to detect mutations	Qualitative but dependent on mutations being accurately detected	Large amount of starting material required	8,157
m ⁶ A-LAIC-seq	Immunoprecipitation of polyA selected transcripts with m ⁶ A antibody followed by sequencing of eluate and supernatant Calling a methylated site requires both enrichment in eluate and depletion of the same region in the supernatant	Medium	Dependent on antibody specificity	158
m ⁶ A ELISA	ELISA-based method to detect the amount of m ⁶ A antibody-enriched RNA	Medium	Dependent on antibody specificity and lack of contaminations in normalization controls	159
Nim-seq	Harnesses chemical properties of 2'-O-methylation to expose base and then adaptors added and sequenced	Nucleoside resolution, more sensitive than RiboMeth-seq which takes advantage of 2'-O-methylation resistance to alkaline hydrolysis	–	160
m ⁶ A melting-qPCR	Harnesses capacity of different polymerases to retrotranscribe N ⁶ -adenosine methylated or unmethylated regions to do comparative RT-qPCR	Medium sensitivity	–	161
SMRTseq and nanopore	Transcriptome-wide mapping of modifications based on detecting change of kinetic incorporation of new bases or travelling through pores	High qualitative information if optimized for appropriate base detection	High error rates if not optimized	162–165

Technique	Description	Sensitivity	Limitations	Refs.
mClickseq	Click chemistry to attach small molecules to methylated substrates for targeted degradation Uses enzymes to introduce alkylne rather than methyl group	Highly accurate	Measures depletion rather than enrichment	166
scDARTseq	Single-cell m ⁶ A profiling approach that can map methylomes of thousands of cells Reveals that most transcripts are methylated in a small fraction of cells and there is a high degree of methylation heterogeneity	Highly sensitive for single-cell analyses	–	5
T3 DNA ligase-qPCR and SELECT	Harness changes in ligation efficiency of methylated bases T3 DNA ligase displays significantly higher selectivity for unmethylated adenosines than m ⁶ A, which can be used with qPCR to compare methylation levels in different samples In SELECT, m ⁶ A hinders Bst DNA polymerase elongation and ligation efficiency of nicks and uses qPCR for quantification	Highly sensitive at specific sites	–	167,168

Detection and high-throughput approaches for mapping of m⁶A in RNA offer the advantage that they can inform on both the presence of a modification in RNA and its precise location at single-nucleotide resolution. Several of the antibody-based techniques, however, have the caveat that antibodies may bind to non-specific sequences resulting in a high degree of false-positives sites. m⁶A, N⁶-methyladenosine; MazF, RNA endonuclease cleaves only non-methylated RNA in ACA sequence but not m⁶ACA; MAZTERseq, RNA digestion via m⁶A sensitive RNase; miCLIP, m⁶A individual nucleotide resolution crosslinking and immunoprecipitation; MS, mass spectrometry; qPCR, quantitative PCR; RT, reverse transcriptase; SCARLET, site-specific cleavage and radioactive labelling of the modified nucleotides followed by ligation-assisted extraction and thin-layer chromatography; scDARTseq, single-cell deamination adjacent to RNA modification targets; SELECT, single-base elongation-based and ligation-based qPCR amplification; SMRTseq, single-molecule real-time sequencing; TLC, thin-layer chromatography; UHPLC, ultra-high performance liquid chromatography.

Table 2 |

Enzymes that regulate adenine methylation

Enzymes	Substrates	Prevalence	Refs.
<i>Methyltransferases</i>			
METTL3–METTL14	m ⁶ A mRNAs	25% of mRNAs ^{3,4}	6,169
IME4	m ⁶ A mRNAs	NA	170
METTL16	m ⁶ A snRNA, mRNAs, and other ncRNAs	NA	65,66,171
PCIF1	m ⁶ Am mRNA cap	30% of mRNAs	172–175
CMTR1	Am mRNA	NA	176
FBL	Am rRNA	40–100% ⁵⁶	177–180
TRMT61A	m ¹ A58 tRNA	Most tRNAs ¹⁸¹	182
TRMT61B	m ¹ A nuclear encoded tRNA	NA	183
TRMT10B	m ¹ A nuclear encoded tRNA	NA	184
TRMT10C	m ¹ A mitochondrial mRNA	NA	185
DIM1	m ^{6,2} A 18S rRNA A1850, 1851	NA	186–188
METTL4	m ⁶ Am snRNA	NA	189,190
<i>Demethylases</i>			
FTO	m ⁶ A, m ⁶ Am RNA	NA	10,126
ALKBH5	m ⁶ A RNA	NA	9
ALKBH1	m ¹ A, m ⁵ C and hm ⁵ C tRNA	NA	191,192
ALKBH3	m ¹ A RNA and DNA	NA	193
<i>Binding proteins</i>			
YTHDC1	m ⁶ A mRNAs	NA	194,195
YTHDC2	m ⁶ A mRNAs	NA	100,101
YTHDF1	m ⁶ A mRNAs	NA	38,196
YTHDF2	m ⁶ A mRNAs	NA	4,41
YTHDF3	m ⁶ A mRNAs	NA	4
ELAVL1	m ⁶ A mRNAs	NA	4
eIF3	m ⁶ A mRNAs	NA	37
HNRNPC/G	m ⁶ A mRNAs	NA	26,197
HNRNPA2B1	m ⁶ A mRNAs	NA	44
IGF2BP1–3	m ⁶ A mRNAs	NA	33
FMRP	m ⁶ A mRNAs	NA	34

Am, 2'-*O*-methyladenosine; eIF3, eukaryotic translation initiation factor 3; FMRP, fragile X mental retardation protein; hm⁵C, 5-hydroxymethylcytosine; HNRNP, heterogeneous nuclear ribonucleoprotein; IGF2BP, insulin-like growth factor 2 binding protein; m¹A, N¹-methyladenosine; m⁵C, C5-cytosine methylation; m⁶A, N⁶-methyladenosine; m^{6,2}A, N⁶,N⁶-dimethyladenosine; m⁶Am, N⁶,2'-*O*-dimethyladenosine; NA, not available; ncRNA, non-coding RNA; rRNA, ribosomal RNA; snRNA, small nuclear RNA.